myok-10q_20160331.htm

0001564590-16-019213.txt : 20160512 0001564590-16-019213.hdr.sgml : 20160512 20160512145841 ACCESSION NUMBER: 0001564590-16-019213 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160512 DATE AS OF CHANGE: 20160512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MyoKardia Inc CENTRAL INDEX KEY: 0001552451 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455500552 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37609 FILM NUMBER: 161643287 BUSINESS ADDRESS: STREET 1: 333 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-741-0900 MAIL ADDRESS: STREET 1: 333 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 10-Q 1 myok-10q_20160331.htm 10-Q myok-10q_20160331.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2016

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-37609

MYOKARDIA, INC.

(Exact name of registrant as specified in its charter)

Delaware

44-5500552

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

333 Allerton Ave.

South San Francisco, CA

(Address of principal executive offices)

94080

(Zip Code)

(650) 741-0900

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer		¨		Accelerated filer		¨
Non-accelerated filer		x (Do not check if a smaller reporting company)		Smaller reporting company		¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

The number of outstanding shares of the registrant’s common stock on May 5, 2016 was 27,041,110 shares.

MYOKARDIA, INC.

TABLE OF CONTENTS

	Page
PART I—FINANCIAL INFORMATION		3
Item 1. Condensed Consolidated Financial Statements		3
Condensed Consolidated Balance Sheets as of March 31, 2016 and December 31, 2015 (unaudited)		3
Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2016 and 2015 (unaudited)		4
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2016 and 2015 (unaudited)		5
Notes to Condensed Consolidated Financial Statements (unaudited)		6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		15
Item 3. Quantitative and Qualitative Disclosures About Market Risk		20
Item 4. Controls and Procedures		20
PART II—OTHER INFORMATION		22
Item 1. Legal Proceedings		22
Item 1A. Risk Factors		22
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		49
Item 3. Defaults Upon Senior Securities		50
Item 4. Mine Safety Disclosures		50
Item 5. Other Information		50
Item 6. Exhibits		50
SIGNATURES		51
EXHIBIT INDEX		52

PART I—FINANCIAL INFORMATION

Item 1.

Condensed Consolidated Financial Statements

MYOKARDIA, INC.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

(Unaudited)

	March 31, 2016			December 31, 2015
Assets
Current assets
Cash and cash equivalents	$	99,495		$	112,265
Prepaid expenses and other current assets		1,245			1,282
Total current assets		100,740			113,547
Property and equipment, net		3,007			2,744
Other long term assets		289			289
Total assets	$	104,036		$	116,580
Liabilities and stockholders’ equity
Current liabilities
Accounts payable	$	1,994		$	2,143
Accrued liabilities		4,827			5,633
Deferred revenue		10,649			14,199
Total current liabilities		17,470			21,975
Other long-term liabilities		658			732
Total liabilities		18,128			22,707
Commitments and contingencies (Note 6)
Stockholders’ equity (deficit)
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding		—			—
Common stock, $0.0001 par value, 150,000,000 shares authorized at March 31, 2016 and December 31, 2015; 27,016,082 and 27,053,156 shares, issued and outstanding at March 31, 2016 and December 31, 2015, respectively		3			3
Additional paid-in-capital		159,010			158,555
Accumulated deficit		(73,105	)		(64,685	)
Total stockholders’ equity		85,908			93,873
Total liabilities and stockholders’ equity	$	104,036		$	116,580

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

MYOKARDIA, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

(Unaudited)

	Three Months Ended March 31,
	2016			2015
Collaboration and license revenue	$	3,550		$	3,550
Operating expenses
Research and development		8,130			6,616
General and administrative		3,860			1,765
Total operating expenses		11,990			8,381
Loss from operations		(8,440	)		(4,831	)
Interest and other income, net		20			17
Change in fair value of redeemable convertible preferred stock call option liability		—			314
Net loss and comprehensive loss		(8,420	)		(4,500	)
Cumulative dividend relating to redeemable convertible preferred stock		—			(952	)
Accretion of redeemable convertible preferred stock to redemption value		—			(33	)
Net loss attributable to common stockholders	$	(8,420	)	$	(5,485	)
Net loss per share attributable to common stockholders, basic and diluted	$	(0.32	)	$	(2.47	)
Weighted-average number of common shares used to compute net loss per share, basic and diluted		26,169,152			2,221,751

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

MYOKARDIA, INC.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

	Three Months Ended March 31,
	2016			2015
Cash flows from operating activities:
Net loss	$	(8,420	)	$	(4,500	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		256			254
Stock-based compensation expense		414			35
Gain on sale of equipment		—			(15	)
Change in fair value of redeemable convertible preferred stock call option liability, net		—			(314	)
Change in operating assets and liabilities:
Prepaid expenses and other assets		37			(313	)
Accounts payable		(115	)		323
Accrued liabilities		(666	)		71
Other long term liabilities		(11	)		307
Deferred revenue		(3,550	)		(3,550	)
Net cash used in operating activities		(12,055	)		(7,702	)
Cash flows from investing activities:
Purchases of property and equipment		(562	)		(562	)
Proceeds from sale of equipment		—			134
Net cash used in investing activities		(562	)		(428	)
Cash flows from financing activities:
Proceeds from issuance of common stock		—			99
Payments of deferred offering costs		(153	)		—
Net cash (used in) provided by financing activities		(153	)		99
Net decrease in cash and cash equivalents		(12,770	)		(8,031	)
Cash and cash equivalents, beginning of period		112,265			43,648
Cash and cash equivalents, end of period	$	99,495		$	35,617
Supplemental disclosures of noncash investing and financing information
Vesting of early exercised options and restricted stock	$	71		$	29
Unpaid portion of property and equipment purchases included in period-end accounts payable	$	13		$	48
Unpaid portion of property and equipment purchases included in period-end accrued liabilities	$	5		$	229
Accretion of dividends on redeemable convertible preferred stock	$	—		$	952
Accretion of redeemable convertible preferred stock to redemption value	$	—		$	33

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MYOKARDIA, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Formation and Business of the Company

MyoKardia, Inc., incorporated under the laws of the State of Delaware in June 2012, is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. We have used our precision medicine platform to generate an initial pipeline of four therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy—hypertrophic cardiomyopathy (“HCM”), and dilated cardiomyopathy (“DCM”). We have discovered and advanced our lead product candidate, MYK-461, into Phase 1 clinical development. In our first Phase 1 clinical trial, we have demonstrated proof of mechanism, or the ability of MYK-461 to reduce cardiac muscle contraction, an important biomarker of disease. We intend to expand our approach to deliver treatments with disease-modifying potential for patients with other forms of genetically-driven heart failure.

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Through March 31, 2016, the Company has financed its operations through an initial public offering (“IPO”) and private placements of redeemable convertible preferred stock and funds received in connection with a license and collaboration agreement with Aventis Inc., a wholly-owned subsidiary of Sanofi S.A., entered into in August 2014 (the “Collaboration Agreement”) (See Note 4). The Company received net proceeds of $93.9 million from the sale of shares of its Series A, A-1 and B redeemable convertible preferred stock. On November 3, 2015, the Company completed its IPO of 6,253,125 shares of common stock at an offering price of $10.00 per share, resulting in net proceeds of approximately $55.6 million, after deducting underwriting discounts, commissions and offering costs. The Company has incurred significant losses and negative cash flows from operations. As at March 31, 2016, the Company had an accumulated deficit of $73.1 million and cash and cash equivalents of $99.5 million, which it believes will be sufficient to fund its planned operations through at least the next twelve months.

The accompanying unaudited Condensed Consolidated Financial Statements, in the opinion of management, include all adjustments which the Company considers necessary for the fair statement of the Condensed Consolidated Results of Operations and Comprehensive Loss and Cash Flows for the interim periods covered and the Condensed Consolidated Financial Position of the Company at the date of the balance sheets. The consolidated financial statements of the Company as at December 31, 2015 included the Company’s accounts and have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2016, or any other future period.

The accompanying unaudited Condensed Consolidated Financial Statements and related financial information should be read in conjunction with the Company’s audited consolidated financial statements and the related notes thereto for the year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 18, 2016 (the “Annual Report”).

2. Summary of Significant Accounting Policies

Significant accounting policies are described in Note 2 to the consolidated financial statements for the year ended December 31, 2015 included in the Annual Report. There have been no changes to the Company’s significant accounting policies during the three months ended March 31, 2016.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s consolidated financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), the Company meets the definition of an emerging growth company, and has irrevocably elected to opt out of the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.

In March 2016, the FASB issued Accounting Standard Update (“ASU”) No. 2016-10, Revenue from Contracts, which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU will provide a more robust framework

MYOKARDIA, INC.

Notes to Condensed Consolidated Financial Statements—(Continued)

(Unaudited)

for recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation. This framework will help to improve comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets and provide more useful information to users of financial statements through improved disclosure requirements. For a public entity, the amendments in ASU 2016-10 are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Company has not determined the potential effects of this standard on its consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Share-Based Compensation, with the objective to identify, evaluate, and improve areas of generally accepted accounting principles (GAAP) for which cost and complexity can be reduced while maintaining or improving the usefulness of the information provided to users of financial statements. The areas for simplification in ASU 2016-09 involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public business entities, the amendments in ASU 2016-09 are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for any entity in any interim or annual period. The Company is currently evaluating the impact of this standard on its consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02 (Topic 842), Leases. ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has not determined the potential effects of this standard on its consolidated financial statements.

In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern. The new standard provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.

In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. ASU 2014-12 requires that a performance target that affects vesting and could be achieved after the requisite service period be treated as a performance condition. ASU 2014-12 is effective for the Company in its first quarter of 2016 with early adoption permitted. The Company has determined that the adoption of this standard did not have a material impact on its consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The ASU is effective for public entities for annual and interim periods beginning after December 15, 2017, with early adoption for fiscal 2017 permitted. The Company has not determined the potential effects of this standard on its consolidated financial statements.

MYOKARDIA, INC.

Notes to Condensed Consolidated Financial Statements—(Continued)

(Unaudited)

3. Fair Value Measurements

Financial assets and liabilities are recorded at fair value. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

Level 2—Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.

Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

The following table sets forth a summary of the changes in the fair value of the Company’s Level 1 financial instruments as follows (in thousands):

	Fair Value Measurements at March 31, 2016
	Total		Level 1		Level 2		Level 3
Assets
Money Market funds	$	99,060	$	99,060	$	—	$	—

	Fair Value Measurements at December 31, 2015
	Total		Level 1		Level 2		Level 3
Assets
Money Market funds	$	111,533	$	111,533	$	—	$	—

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments as follows (in thousands):

	Convertible preferred stock
	call option liability, net
Balance at December 31, 2014	$	314
Change in fair value recorded in statement of operations and comprehensive loss		(314	)
Balance at March 31, 2015	$	—

4. Collaboration and License Agreement

Sanofi (Aventis Inc.)

In August 2014, the Company entered into the Collaboration Agreement with Aventis Inc., a wholly-owned subsidiary of Sanofi S.A. (together with Aventis, Inc., “Sanofi”), for the research, development and potential commercialization of pharmaceutical products for the treatment, prevention and diagnosis of hypertrophic and dilated cardiomyopathy, as well as potential additional indications.

Pursuant to the Collaboration Agreement, in addition to potential future royalty payments, Sanofi agreed to provide up to $200.0 million in financial consideration to the Company consisting of the following components:

a $35.0 million upfront cash payment;

a $10.0 million initial equity investment;

a $25.0 million milestone-based contingent payment;

MYOKARDIA, INC.

Notes to Condensed Consolidated Financial Statements—(Continued)

(Unaudited)

up to an $85.0 million project continuation payment if Sanofi elects to extend the term of the research collaboration beyond December 31, 2016, as described below; and

up to $45.0 million in funding from Sanofi of approved in-kind research and clinical activities over a four-year period.

The Company is also entitled to receive tiered royalties beginning in the mid-single digits to the mid-teens on net sales of certain hypertrophic cardiomyopathy (“HCM”) and dilated cardiomyopathy (“DCM”) finished products outside the United States and on net sales of certain DCM finished products in the United States. Sanofi is eligible to receive tiered royalties beginning in the mid-single digits to the low teens on the Company’s net sales of certain HCM finished products in the United States.

The Collaboration Agreement covers three main research programs, “HCM1” (“HCM-1” or “MYK-461”), “HCM2” (“HCM-2”) and “DCM1” (“DCM-1”). The Company is solely responsible for conducting research and development activities through early human efficacy studies, except for specified research activities to be conducted by Sanofi. The estimated completion of proof-of-concept phases are staggered, depending on the program. Thereafter, the Company will lead worldwide development and United States commercial activities for the MYK-461 and HCM-2 programs, Sanofi will lead global development and commercial activities for DCM-1 and Sanofi will lead ex-United States development and commercial activities for the MYK-461 and HCM-2 programs where it has ex-United States commercialization rights. Sanofi also has the option to co-promote in the United States for potential expanded cardiovascular diseases outside of the genetically targeted indications for the MYK-461 and HCM-2 programs, with the Company having the option to co-promote the DCM-1 program in the United States.

The Company accounted for the Collaboration Agreement by evaluating each of the financial components discussed above:

$35.0 million upfront payment. The Company received a non-refundable upfront payment and identified the following performance obligations at the inception of the Collaboration Agreement: (i) the transfer of intellectual property rights and know-how (license), (ii) the obligation to provide certain limited research and development services during the term of the license agreement and (iii) the obligation to participate on the development and commercialization committees. The Company applied the guidance under ASC 605-25, Multiple Element Arrangements, to account for this upfront payment. The Company evaluated the underlying goods and services delivered under the Collaboration Agreement and concluded that the performance obligations do not have standalone value, and accordingly accounted for the deliverables as one unit of accounting. The $35.0 million payment was recorded by the Company as deferred revenue on its consolidated balance sheet upon receipt, which the Company is recognizing as revenue on a straight-line basis over the expected term of research and development services through December 31, 2016 because there is not a more discernible pattern of performance in which the research and development services occur. During the three months ended March 31, 2016 and 2015, the Company recognized $3.6 million and $3.6 million of revenue, under the Collaboration Agreement, respectively. As of March 31, 2016 and December 31, 2015, the Company had recorded deferred revenue on its consolidated balance sheet of $10.6 million and $14.2 million, respectively.

$10.0 million upfront investment in Series A-1 redeemable convertible preferred stock. In August 2014, the Company entered into a Series A-1 redeemable convertible preferred stock purchase agreement with Sanofi. The Agreement was signed as a separate transaction from the Collaboration Agreement. Pursuant to the stock purchase agreement, the Company sold 6,666,667 shares of Series A-1 redeemable convertible preferred stock to Sanofi at $1.50 per share. The Company concluded that the $1.50 per share price represented the fair value of the redeemable convertible preferred stock issued.

$25.0 million milestone-based payment. The Company is eligible to receive a one-time, non-refundable, non-creditable payment of $25.0 million upon the submission of an investigational new drug application for any DCM-1 development candidate to the FDA or a comparable regulatory authority in Europe or another major market country for any DCM-1 product. The Company will account for this milestone payment separately from the rest of the agreement and recognize revenue upon achievement of the milestone. The Company had not achieved this milestone as of March 31, 2016.

MYOKARDIA, INC.

Notes to Condensed Consolidated Financial Statements—(Continued)

(Unaudited)

Up to $85.0 million continuation payments. Under the Collaboration Agreement, Sanofi must determine by December 31, 2016 whether or not to continue the Collaboration Agreement. Sanofi agreed that if it so elects to continue the Collaboration Agreement, it will pay:

a one-time, non-refundable, non-creditable cash payment of $45.0 million

an additional $40.0 million in connection with the purchase of the Company’s preferred stock, assuming (i) the Company had not previously closed either a Qualified IPO (at which time this obligation would terminate) or a private financing prior to a Qualified IPO and (ii) Sanofi had not previously purchased shares of the Company’s stock pursuant to such rights to purchase the Company’s capital stock in accordance with the terms of the Collaboration Agreement. The $40.0 million payment was reduced by $5.0 million to $35.0 million in connection with Sanofi’s subsequent purchase of shares of the Company’s Series B redeemable convertible preferred stock in April 2015, and the remaining obligation terminated in connection with the Company’s IPO in October 2015.

Sanofi also had a time-restricted right to purchase $40.0 million in shares of the Company’s redeemable convertible preferred stock at the discounted price, which would have satisfied the $40.0 million obligation to purchase shares of the Company’s capital stock in connection with the continuation decision. Sanofi’s option to purchase $40.0 million of additional shares of the Company’s redeemable convertible preferred stock at the discounted price expired upon the closing of the Series B redeemable convertible preferred stock financing in April 2015.

The Company believes that the continuation payments have significant uncertainty and are outside the control of the Company because Sanofi has sole discretion to determine whether or not to continue, and will therefore account for these potential payments separate from the other deliverables in this agreement.

The Company determined that Sanofi’s right to purchase the redeemable convertible preferred stock at the discounted price, and the Company’s corresponding obligation to issue this additional redeemable convertible preferred stock, represented a freestanding financial instrument. The freestanding convertible preferred stock call option liability was initially recorded at its fair value of $0.7 million in 2014. The Company recorded a decrease in the fair value of this liability of $0.3 million and $0.4 million in the consolidated statements of operations and comprehensive loss during the years ended December 31, 2015 and 2014, respectively.

As of March 31, 2016, Sanofi had not provided the confirmation of continuation under the Collaboration Agreement.

Up to $45.0 million in-kind research and collaboration activities. Sanofi can fund up to $45.0 million of pre-approved funding of research and collaboration activities. Since Sanofi will pay its vendors and personnel directly as per the Collaboration Agreement, the Company will not receive cash from Sanofi and therefore will not account for the funding of the in-kind services.

5. Balance Sheet Components

Property and Equipment

Property and equipment consist of the following (in thousands):

	March 31, 2016			December 31, 2015
Scientific equipment	$	4,462		$	3,995
Furniture and equipment		352			301
Capitalized software		225			225
Leasehold improvements		304			303
Total		5,343			4,824
Less: Accumulated depreciation and amortization		(2,336	)		(2,080	)
Property and equipment, net	$	3,007		$	2,744

Depreciation and amortization expense was $0.3 million and $0.3 million for the three months ended March 31, 2016 and 2015, respectively.

MYOKARDIA, INC.

Notes to Condensed Consolidated Financial Statements—(Continued)

(Unaudited)

Accrued Liabilities

Accrued liabilities consist of the following (in thousands):

	March 31, 2016		December 31, 2015
Payroll and related expenses	$	1,522	$	2,515
Clinical research and development		2,478		2,145
Legal and accounting fees		371		33
Other		456		940
Total accrued liabilities	$	4,827	$	5,633

6. Commitments and Contingencies

Purchase Commitments

The Company conducts product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. The Company has contractual arrangements with these organizations; however, these contracts are generally cancelable on 30 days’ notice and the obligations under these contracts are largely based on services performed.

Facility Leases

On June 29, 2012, the Company entered into a 66-month lease for approximately 12,000 square feet of office and laboratory space in South San Francisco with annual payments of approximately $0.5 million. In connection with this lease agreement, the Company also entered into a shared facilities and services agreement with Global Blood Therapeutics, Inc. (“GBT”), a co-tenant in the office building (See Note 10). In October 2014, the Company entered into a lease assignment agreement with the owner of the building and GBT to allow GBT to sublease the Company’s portion of the building beginning in March 2015. For the three months ended March 31, 2016, the Company recorded approximately $0.1 million of sublease income and $0.1 million of sublease expense, which is recorded in interest and other income, net in the consolidated statements of operations and comprehensive loss.

On September 15, 2014, the Company entered into a five-year lease for approximately 34,400 square feet of office and laboratory space in South San Francisco. The Company may extend the lease for an additional three year term. The initial annual lease payments are $1.3 million, increasing to $1.6 million in the final year of the agreement. The lease period commenced in January 2015. The Company received a lease abatement for the first three months of the lease term, which is recorded as deferred rent and recognized over the lease term.

The Company has provided deposits for letters of credit totaling $0.3 million to secure its obligations under its leases, which have been classified as long-term assets on the Company’s consolidated balance sheet as of March 31, 2016.

Rent expense, net was $0.3 million and $0.3 million for the three months ended March 31, 2016, and 2015, respectively.

Contingencies

From time to time, the Company may have contingent liabilities that arise in the ordinary course of business activities. The Company accrues for such a liability when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were no contingent liabilities requiring accrual or disclosure as of March 31, 2016, or December 31, 2015.

Guarantees and Indemnifications

The Company enters into standard indemnification arrangements in the ordinary course of business.

Pursuant to certain of these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company’s technology. The term of these

MYOKARDIA, INC.

Notes to Condensed Consolidated Financial Statements—(Continued)

(Unaudited)

indemnification arrangements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made.

The Company indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws, and agreements providing for indemnification entered into with its officers and directors. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity.

The maximum amount of potential future indemnification of directors and officers is unlimited; however, the Company currently holds director and officer liability insurance. This insurance allows the transfer of risk associated with its exposure and may enable it to recover a portion of any future amounts paid.

The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.

7. Stockholders’ Equity

Common Stock Reserved for Issuance

The Company has reserved shares of common stock for issuance as follows:

	March 31, 2016		December 31, 2015
Options issued and outstanding		1,910,181		1,318,647
Shares available for issuance under 2015 Stock Option and Incentive Plan		942,611		1,497,071
Shares available for issuance under 2015 Employee Stock Purchase Plan		255,000		255,000
Total		3,107,792		3,070,718

Redeemable Convertible Preferred Stock

Prior to the IPO in October 2015, the Company had 62,235,313 shares of redeemable convertible preferred stock outstanding with a par value of $0.0001 per share, of which 38,500,000 were designated Series A redeemable convertible preferred stock, 6,666,667 were designated Series A-1 redeemable convertible preferred stock, and 17,068,646 were designated Series B redeemable convertible preferred stock. As disclosed in the Company’s Form 10-K for the year ended December 31, 2015, the Company accreted redeemable convertible preferred stock to redemption value and also accreted dividends in relation to these shares of redeemable convertible preferred stock. For the three months ended March 31, 2015, the Company accreted redeemable convertible preferred stock to redemption value by $33,000 and accreted dividends on redeemable convertible preferred stock of $952,000.

8. Stock-Based Compensation

The Company classifies stock-based compensation expense in the accompanying condensed consolidated statements of operations and comprehensive loss based on the department to which a recipient belongs. The following table sets forth stock-based compensation expense related to options granted to employees and consultants for all periods presented (in thousands):

	Three Months Ended March 31,
	2016		2015
Research and development	$	174	$	18
General and administrative		240		17
Total	$	414	$	35

MYOKARDIA, INC.

Notes to Condensed Consolidated Financial Statements—(Continued)

(Unaudited)

The following summarizes option activity under the 2012 Equity Incentive Plan and 2015 Stock Option and Incentive Plan:

	Shares Subject to			Weighted Average
	Outstanding Options			Exercise Price Per Share
Balance at December 31, 2015		1,318,647			2.29
Options granted		605,134			8.80
Options exercised		—			—
Options canceled		(13,600	)		10.00
Balance at March 31, 2016		1,910,181			4.30

In relation to stock options to purchase common stock that vest upon the achievement of performance criteria, no stock-based compensation expense had been recorded as of March 31, 2016, because the Company concluded that the achievement of the applicable performance criteria had not been considered probable.

9. Net Loss per Share Attributable to Common Stockholders

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts):

	Three Months Ended March 31,
	2016			2015
Numerator
Net loss	$	(8,420	)	$	(4,500	)
Cumulative dividends on redeemable convertible preferred stock		—			(952	)
Accretion of redeemable convertible preferred stock to redemption value		—			(33	)
Net loss attributable to common stockholders, basic and diluted	$	(8,420	)	$	(5,485	)
Denominator
Weighted average shares outstanding		27,024,638			3,752,389
Less: weighted average shares subject to repurchase		(855,486	)		(1,530,638	)
Weighted average shares used to compute basic and diluted net loss per share		26,169,152			2,221,751
Net loss per share attributable to common stockholders: Basic and diluted	$	(0.32	)	$	(2.47	)

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:

	March 31,
	2016		2015
Common stock subject to repurchase		806,035		1,465,685
Stock options to purchase common stock		1,910,181		458,887

10. Related Party Transactions

In September 2012, the Company began receiving consulting and management services pursuant to an unwritten agreement with Third Rock Ventures, which is one of the Company’s largest shareholders. Charles Homcy and Kevin Starr, both directors of the Company, are general partner and partner, respectively, of Third Rock Ventures. The consulting fees paid to Third Rock Ventures were incurred by the Company in the ordinary course of business, and were $22,000 and $31,000 for the three months ended March 31, 2016 and 2015, respectively. As of March 31, 2016 and December 31, 2015, the Company had an outstanding liability to Third Rock Ventures of $23,000 and $13,000.

Effective July 29, 2013, the Company entered into a shared facilities and services agreement with GBT, a company that was majority-owned by Third Rock Ventures as of such date. In connection with that agreement, the Company reimbursed GBT for shared facilities and equipment of the Company’s former corporate headquarters location. During the three months ended March 31, 2016 and 2015, the Company reimbursed expenses and equipment of zero and $33,000, respectively, to GBT. There was no outstanding

MYOKARDIA, INC.

Notes to Condensed Consolidated Financial Statements—(Continued)

(Unaudited)

liability to GBT as of March 31, 2016 and December 31, 2015. In October 2014, the Company entered into a lease assignment agreement with the owner of the former headquarters building and GBT to allow GBT to sublease the Company’s portion of the office after the Company relocated to its new corporate headquarters.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operation

You should read the following management’s discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q and with our audited consolidated financial statements and notes thereto for the year ended December 31, 2015, included in our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the U.S. Securities and Exchange Commission (SEC) on March 18, 2016 (the “Annual Report”).

Special note regarding forward-looking statements

This report contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed in the forward-looking statements. The statements contained in this report that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “strategy,” “target,” “will,” “would” and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section titled “Risk Factors” included under Part II, Item 1A below. Furthermore, such forward-looking statements speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

Overview

We are a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. We have used our precision medicine platform to generate an initial pipeline of four therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy—hypertrophic cardiomyopathy (“HCM”) and dilated cardiomyopathy (“DCM”). We have discovered and advanced our lead product candidate, MYK-461, into Phase 1 clinical development. In our first Phase 1 clinical trial, we have demonstrated proof of mechanism, or the ability of MYK-461 to reduce cardiac muscle contraction, an important biomarker of disease. We intend to expand our approach to deliver treatments with disease-modifying potential for patients with other forms of genetically-driven heart failure.

Financial Overview

We have not generated net income from operations, and, as of March 31, 2016, we had an accumulated deficit of $73.1 million, primarily as a result of research and development and general and administrative expenses.

To date, all of our revenue has been derived from non-refundable payments under the license and collaboration agreement we entered into with Aventis Inc., a wholly-owned subsidiary of Sanofi S.A., in August 2014, which we refer to as the Collaboration Agreement, and we have not yet generated any revenue from product sales. We have never been profitable and have incurred net losses in each year since commencement of our operations. We expect to incur significant and increasing losses from operations for the foreseeable future, and we can provide no assurance that we will ever generate significant revenue or profits.

Through March 31, 2016, we have financed our operations through an IPO and private placements of redeemable convertible preferred stock and funds received in connection with a license and collaboration agreement with Aventis Inc., a wholly-owned subsidiary of Sanofi S.A., entered into in August 2014 (the “Collaboration Agreement”). We received net proceeds of $93.9 million from the sale of shares of our Series A, A-1 and B redeemable convertible preferred stock. On November 3, 2015, we completed our IPO of 6,253,125 shares of common stock at an offering price of $10.00 per share, resulting in net proceeds of approximately $55.6 million, after deducting underwriting discounts, commissions and offering costs. As of March 31, 2016, we had an accumulated deficit of $73.1 million and cash and cash equivalents of $99.5 million, which we believe will be sufficient to fund our planned operations through at least the next twelve months.

We have no manufacturing facilities, and all of our manufacturing activities are contracted out to a third party. Additionally, we currently utilize third-party clinical research organizations (“CROs”) to carry out our clinical development and trials. We do not yet have a sales organization.

We expect to incur substantial expenditures in the foreseeable future for the advancement of our precision medicine platform and the discovery, development and potential commercialization of MYK-461, our lead product candidate, and additional product candidates that we intend to pursue. Specifically, we expect to continue to incur substantial expenses in connection with our ongoing Phase 1 clinical trials and any Phase 2 and Phase 3 clinical trials that we may conduct for MYK-461. We will need substantial additional funding to support our operating activities as we advance MYK-461 and other potential product candidates through clinical development, seek regulatory approval and prepare for, and if approved, proceed to commercialization. Adequate funding may not be available to us on acceptable terms, or at all.

License and Collaboration Agreement with Sanofi

In August 2014, we entered into the Collaboration Agreement with Aventis, Inc., a wholly-owned subsidiary of Sanofi S.A., that covers three main research programs: our first program in HCM (referred to as MYK- 461 or HCM-1), a second program in HCM (referred to as HCM-2) and our first program in DCM (referred to as DCM-1). For purposes of this presentation, we refer to Sanofi as our co-party to the Collaboration Agreement.

Under the Collaboration Agreement, we are responsible for conducting research and development activities through early human efficacy studies, except for specified research activities to be conducted by Sanofi. Thereafter, we will lead worldwide development and U.S. commercial activities for the MYK-461 and HCM-2 programs, Sanofi will lead global development and commercial activities for DCM-1 and Sanofi will lead commercial activities for the MYK-461 and HCM-2 programs where it has ex-U.S. commercialization rights. Sanofi also has the option to co-promote the MYK-461 and HCM-2 programs in the United States only in the event of a potential expanded cardiovascular disease indication outside of the genetically targeted indications for MYK-461 and HCM-2. We have co-commercialization rights to DCM-1 in the United States, at our option.

We are entitled to receive tiered royalties ranging from the mid-single digits to the mid-teens on net sales of certain HCM and DCM finished products outside the United States and on net sales of certain DCM finished products in the United States. Sanofi is eligible to receive tiered royalties ranging from the mid-single digits to the low teens on our net sales of certain HCM finished products in the United States.

Under the Collaboration Agreement, Sanofi also agreed to provide up to $200.0 million in upfront and milestone payments, equity investments and research and development support. To date, of such amount, we have received from Sanofi an initial non-refundable upfront cash payment of $35.0 million and equity investments of $10.0 million in exchange for Series A-1 redeemable convertible preferred stock, $5.0 million in exchange for Series B redeemable convertible preferred stock and $9.0 million in exchange for shares of our common stock in our IPO. The total payments we were originally eligible to receive also include a $45.0 million continuation payment, a $25.0 million milestone-based payment, and an obligation from Sanofi to purchase an additional $40.0 million of our capital stock if Sanofi provided notice of its intent to continue the collaboration prior to December 31, 2016. Under the Collaboration Agreement, Sanofi’s obligation to purchase the additional $40.0 million of our capital stock (which was reduced by $5.0 million for its purchase of the Series B redeemable convertible preferred stock) terminated in connection with the closing of our IPO in November 2015. Additionally, we are eligible to receive up to $45.0 million of approved in-kind research and clinical activities.

Critical Accounting Policies and Significant Judgments and Estimates

This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Our significant accounting policies are more fully described in Note 2 of our Annual Report. We believe that the accounting policies discussed in our Annual Report are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgments and estimates. There have been no changes to our significant accounting policies during the three months ended March 31, 2016.

Components of Operating Results

Collaboration and License Revenue

We generate revenue from the Collaboration Agreement with Sanofi for the development and commercialization of products under the collaboration.

Operating Expense

Research and Development Expenses

Research and development expenses consist of salaries and benefits, including stock-based compensation, lab supplies and facility costs, as well as fees paid to CROs to conduct certain research and development activities on our behalf. Amounts incurred in connection with collaboration and license agreements are also included in research and development expense. Payments made to third parties in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.

General and Administrative Expenses

General and administrative expenses consist principally of personnel-related costs, professional fees for legal, consulting, audit and tax services, market research, rent and other general operating expenses not otherwise classified as research and development expenses.

Change in Fair Value of Redeemable Convertible Preferred Stock Call Option Liability

We determined that our obligation to issue additional shares of our redeemable convertible preferred stock represented a freestanding financial instrument. The freestanding redeemable convertible preferred stock call option liability was initially recorded at fair value, with fair value changes recognized as increases or reductions in the consolidated statements of operations and comprehensive loss. We continued to adjust the liability for changes in fair value until the issuance of our Series B redeemable convertible preferred stock in April 2015, upon which no further remeasurement was required. We had recorded a redeemable convertible preferred stock call option liability in August 2014 related to the Collaboration Agreement, which was extinguished in April 2015 at the time of the closing of the Series B redeemable convertible preferred stock financing.

Interest and Other Income (Expense), Net

Other income (expense), net consists primarily of interest income earned on our cash and cash equivalents.

Results of Operations

Comparison of the Three-Month Periods Ended March 31, 2016 and 2015

	Three Months Ended March 31,						Increase
	2016			2015			(Decrease)
	(in thousands)
Collaboration and license revenue	$	3,550		$	3,550		$	—
Operating expenses:
Research and development		8,130			6,616			1,514
General and administrative		3,860			1,765			2,095
Loss from operations		(8,440	)		(4,831	)		3,609
Interest and other income (expense), net		20			17			3
Change in fair value of redeemable convertible preferred stock call option liability		—			314			(314	)
Net loss and comprehensive loss	$	(8,420	)	$	(4,500	)		3,920

Collaboration and License Revenue

Collaboration and license revenue of $3.5 million during the three months ended March 31, 2016 was equal to the $3.5 million during the three months ended March 31, 2015. The entire amount for both periods relate to revenue we recognized from the initial upfront payment of $35.0 million under the Collaboration Agreement with Sanofi we entered into in August 2014.

Research and Development Expenses

Research and development expenses increased $1.5 million, or 23%, from $6.6 million for the three months ended March 31, 2015 to $8.1 million for the three months ended March 31, 2016. The increase in research and development expenses was primarily due to an increase in clinical trial, manufacturing and toxicology study expenses of $0.7 million for MYK-461, an increase in professional services of $0.4 million, and an increase in personnel expenses of $0.3 million as a result of an increase in our employee headcount. For the periods presented, substantially all of our research and development expenses related to MYK-461 and our other preclinical drug candidates.

We expect research and development expenses to increase in future periods as we continue the development of our lead product candidate, MYK-461, in clinical trials as well as preclinical and subsequent clinical activities for our HCM-2 and DCM-1 programs. As product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials, we expect that our research and development expenses will increase substantially in the future.

General and Administrative Expenses

General and administrative expenses increased $2.1 million, or 119%, from $1.8 million for the three months ended March 31, 2015 to $3.9 million for the three months ended March 31, 2016. The increase in general and administrative expenses was primarily due to increases in personnel expenses of $0.8 million, an increase in professional services expenses of $0.6 million primarily for legal and recruiting costs, and facilities and office related expenses of $0.5 million, as we expanded our operations.

We expect general and administrative expenses to continue to increase in future periods, reflecting both the increased costs in connection with the future commercialization of MYK-461, as well as an expanded infrastructure and increased professional fees associated with being a public company.

Interest and Other Income (Expense), Net

Interest and other income was $17,000 and $20,000 for the three months ended March 31, 2015 and 2016, respectively. Interest income for both periods was attributable to the interest earned on our cash and cash equivalents.

Change in Fair Value of Redeemable Convertible Preferred Stock Call Option Liability

The change in fair value of redeemable convertible preferred stock call option liability changed from a gain of $314,000 during the three months ended March 31, 2015 to zero for the three months ended March 31, 2016. The change resulted from recording a gain related to the decline in the fair value of the Series A-1 redeemable convertible preferred stock call option liability during the three months ended March 31, 2015.

Liquidity and Capital Resources

Since our inception, we have financed our operations primarily through private placements of our equity securities, payments received in connection with the Collaboration Agreement, and our IPO. During 2014, we received net proceeds of $28.9 million from the sale of Series A and Series A-1 redeemable convertible preferred stock and, in August 2014, we received an upfront payment of $35.0 million from Sanofi in connection with the entry into the Collaboration Agreement. In April 2015, we received net proceeds of $45.8 million from the sale of Series B redeemable convertible preferred stock. Pursuant to the IPO in October 2015, we received net proceeds of $55.6 million, net of underwriting discounts, commissions and offering costs, and as of March 31, 2016, we had cash and cash equivalents of $99.5 million.

To date, we have not generated any revenue from product sales. We do not know when, or if, we will generate any revenue from product sales and do not expect to generate significant revenue from product sales unless and until we obtain regulatory approval of and commercialize MYK-461 or other product candidates.

We expect that our existing cash and cash equivalents will provide sufficient funds to sustain operations through at least the next 12 months based on our existing business plan. However, we expect to incur substantial expenditures in the foreseeable future for the advancement of our precision medicine platform and the discovery, development and potential commercialization of MYK-461 and any additional product candidates. Specifically, we have incurred and we expect to continue to incur substantial expenses in connection with our Phase 1 clinical trials for MYK-461 and any Phase 2 or Phase 3 clinical trials that we may conduct. Furthermore, if our Phase 1 and potential Phase 2 and 3 clinical trials are successful, or our other product candidates enter clinical trials or the discovery stage, we will need to raise additional capital in order to further advance our product candidates towards regulatory approval.

We will continue to require additional financing to develop our product candidates and fund operations for the foreseeable future through equity or debt financings, collaborative or other arrangements with corporate sources, or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. We anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including:

the rate of progress and the cost of our clinical trials of MYK-461;

the rate and progress and the cost of our preclinical studies and planned clinical trials for our DCM-1 program;

the number of product candidates that we intend to develop using our precision medicine platform;

the costs of research and preclinical studies to support the advancement of other product candidates into clinical development;

the timing of, and costs involved in, seeking and obtaining approvals from the FDA and comparable foreign regulatory authorities, including the potential by the FDA or comparable regulatory authorities to require that we perform more studies than those that we current expect;

our ability to receive funding under our collaboration with Sanofi, and the timing of receipt of any such funding;

the costs of preparing to manufacture MYK-461 on a larger scale;

the costs of commercialization activities if MYK-461 or any future product candidate is approved, including the formation of a sales force;

the degree and rate of market acceptance of any products launched by us or our partners;

the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

our need and ability to hire additional personnel;

our ability to enter into additional collaboration, licensing, commercialization or other arrangements and the terms and timing of such arrangements; and

the emergence of competing technologies or other adverse market developments.

We may seek funds through borrowings or additional rounds of financing, including private or public equity or debt offerings and collaborative arrangements with corporate partners. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to others technologies, product candidates or programs that we would prefer to develop and commercialize ourselves.

Cash Flows

The following table sets forth the primary sources and uses of cash for each of the periods presented below (in thousands):

	Three Months Ended March 31,
	2016			2015
	(in thousands)
Cash Flows from Continuing Operations:
Net cash used in operating activities	$	(12,055	)	$	(7,702	)
Net cash used in investing activities		(562	)		(428	)
Net cash (used in) provided by financing activities		(153	)		99
Net decrease in cash and cash equivalents	$	(12,770	)	$	(8,031	)

Cash Used in Operating Activities

Net cash used in operating activities for the three months ended March 31, 2016 was $12.1 million, and was primarily due to the net loss for the period, and was also affected by changes in operating assets and liabilities, including a decrease in deferred revenue of $3.6 million and a decrease in accrued liabilities of $0.7 million.

Net cash used in operating activities for the three months ended March 31, 2015 was $7.7 million, and was primarily due to the net loss for the period, and was also affected by changes in operating assets and liabilities, including a decrease in deferred revenue of $3.5 million and an increase in prepaid expenses of $0.3 million, offset by a decrease in accounts payable of $0.3 million and long term liabilities of $0.3 million.

Cash Used in Investing Activities

Cash used in investing activities for all periods presented consisted primarily of investment in equipment. During the three months ended March 31, 2015, we also had proceeds from sale of equipment.

Cash Provided by Financing Activities

Cash used in financing activities in the three months ended March 31, 2016 consisted of payments of $0.2 million in deferred offering costs. Cash provided by financing activities in the three months ended March 31, 2015 consisted of $0.1 million of funds received as a result of common stock option exercises.

As of March 31, 2016, we had cash and cash equivalents of approximately $99.5 million. We believe that our cash resources are sufficient to meet our cash needs for at least the next 12 months.

Contractual Obligations and Other Commitments

There have been no material changes outside the ordinary course of our business to our contractual obligations during the three months ended March 31, 2016, as compared to those disclosed in our Annual Report.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements as defined in the rules and regulations of the SEC.

Jumpstart Our Business Startups Act of 2012

The Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to “opt out” of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted. This decision to opt out of the extended transition period under the JOBS Act is irrevocable. See Note 2, Summary of Significant Accounting Policies, to our consolidated financial statements appearing in our Annual Report regarding recent accounting pronouncements.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

The market risk inherent in our financial instruments represents the potential loss arising from adverse changes in interest rates or exchange rates. As of March 31, 2016, we had cash and cash equivalents of $99.5 million, consisting of interest-bearing money market accounts, which would be affected by changes in the general level of United States interest rates. However, due to the short-term maturities of our cash and cash equivalents and the low- risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair value of our cash and cash equivalents.

In addition, we are also exposed to foreign currency exchange rate risk inherent in our contracts with research institutions and contract research organizations as certain services are performed by them outside the United States. We have payments due to one Australian vendor in foreign currency. A significant movement in the Australian dollar may have a material impact on our financial position in the future.

We do not believe that inflation, interest rate changes or exchange rate fluctuations had a significant impact on our results of operations for any periods presented.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or

submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.

Our management, with the participation of our Chief Executive Officer and Vice President, Corporate Controller, has evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2016, the end of the period covered by this Quarterly Report on Form 10-Q. Based upon such evaluation, our Chief Executive Officer and Vice President, Corporate Controller have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

We are not currently a party to any material litigation or other material legal proceedings.

Item 1A.

RISK FACTORS

You should consider carefully the following risk factors, together with all the other information in this report, including our consolidated financial statements and notes thereto, and in our other public filings with the SEC. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business.

Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements

Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.

We are a very early-stage company. We were incorporated and commenced operations in June 2012. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our technology, creating and expanding on our precision medicine platform, identifying potential product candidates, undertaking preclinical studies and commencing and conducting Phase 1 clinical trials for our most advanced product candidate, MYK-461. We have not yet demonstrated our ability to successfully complete the clinical development of a product candidate, including the completion of any clinical trials designed to show the efficacy of a product candidate, obtain marketing approvals, manufacture a commercial scale medicine, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Typically, it takes many years to develop a new medicine from the time it is discovered to when it is available for treating patients. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.

In addition, as a new business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition from a company with a research focus to a company capable of supporting larger scale clinical development and commercial activities. If we are not successful in such a transition, our business, results and financial condition will be harmed.

We have a history of significant losses and may not achieve or sustain profitability and, as a result, you may lose all or part of your investment.

Our lead product candidate, MYK-461, is in the early stages of clinical testing and we must conduct significant additional clinical trials before we can seek the regulatory approvals necessary to begin commercial sales of MYK-461 or any other product candidates we may develop. We have incurred operating losses in each year since our inception due to costs incurred in connection with our research and development activities and general and administrative costs associated with our operations. Our net loss for the years ended December 31, 2014 and 2015 was $16.8 million and $22.9 million, respectively. As of March 31, 2016, we had an accumulated deficit of $73.1 million. We expect to incur increasing losses for several years as we continue our research activities and conduct development of, and seek regulatory approvals for, our initial product candidates, and commercialize any approved drugs. If our product candidates fail in clinical trials or do not gain regulatory approval, or if our product candidates do not achieve market acceptance, we will not be profitable. If we fail to become and remain profitable, or if we are unable to fund our continuing losses, you could lose all or part of your investment.

We have never generated any revenue from product sales and may never be profitable.

Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaborators, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our product candidates. We do not anticipate generating revenues from product sales for the foreseeable future, if ever. Our ability to generate future revenue from product sales depends heavily on our success in:

completing research and preclinical and clinical development of our product candidates;

seeking and obtaining regulatory approvals to market product candidates for which we complete clinical trials;

developing a sustainable, scalable, reproducible and transferable manufacturing process for our product candidates;

establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate (in amount and quality) products and services to support clinical development and the market demand, if any, for our product candidates, if approved;

launching and commercializing product candidates for which we obtain regulatory approval, either through a collaboration or, if launched independently, by establishing a sales force, marketing and distribution infrastructure;

obtaining market acceptance of our product candidates and the use of precision medicine as a viable treatment option for cardiovascular diseases;

addressing any competing technological and market developments;

implementing additional internal systems and infrastructure, as needed;

identifying and validating new product candidates from our platform;

maintaining our existing collaboration agreement with Sanofi and negotiating favorable terms in any new collaboration, licensing or other arrangements into which we may enter;

maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and

attracting, hiring and retaining qualified personnel who are suitable to our culture and mission.

Even if one or more of the product candidates that we are developing is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond our expectations if we are required by the U.S. Food and Drug Administration (the “FDA”), the European Medicines Agency (the “EMA”) or other regulatory agencies, domestic or foreign, to perform clinical trials and other studies in addition to those that we currently anticipate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.

We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.

We are currently advancing MYK-461, our lead product candidate, through clinical development, and conducting preclinical discovery and development activities in our other programs, including Investigational New Drug (IND)-enabling studies for our DCM-1 development candidate. Drug development is expensive, and we expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we advance our product candidates in clinical trials.

As of March 31, 2016, our cash and cash equivalents were $99.5 million. In November 2015, we sold 6,253,125 shares of common stock in our IPO, the net proceeds of which totaled approximately $55.6 million, after deducting underwriting discounts, commissions and offering costs. We intend to use our cash and cash equivalents to fund the clinical development of MYK-461 through the completion of Phase 2 clinical trials, the advancement of our ongoing preclinical, discovery and research programs and the expansion of our platform, including the Sarcomeric Human Cardiomyopathy Registry (“SHaRe”), as well as for working capital and general corporate purposes. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic and licensing arrangements or a combination of these approaches. In any event, we will require additional capital to obtain regulatory approval for, and to commercialize, MYK-461 and our other product candidates. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations.

Our funding requirements and the timing of our need for additional capital are subject to change based on a number of factors, including:

the rate of progress and the cost of our clinical trials of MYK-461;

the number of product candidates that we intend to develop using our precision medicine platform;

the costs of research and preclinical studies, including our IND-enabling studies for our DCM-1 development candidate, to support the advancement of other product candidates into clinical development;

our ability to receive funding under our collaboration with Sanofi, and the timing of receipt of any such funding;

the costs of preparing to manufacture MYK-461 on a larger scale;

the costs of commercialization activities if MYK-461 or any future product candidate is approved, including the formation of a sales force;

the degree and rate of market acceptance of any products launched by us or our partners;

the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

our need and ability to hire additional personnel;

our ability to enter into additional collaboration, licensing, commercialization or other arrangements and the terms and timing of such arrangements; and

the emergence of competing technologies or other adverse market developments.

Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at a different stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.

If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially and adversely affect our business, financial condition and results of operations.

Risks Related to Our Precision Medicine Platform and the Discovery and Development of Our Product Candidates

The precision medicine approach we are taking to discover and develop drugs for heritable cardiovascular diseases is novel and may never lead to marketable products.

We have concentrated our therapeutic product research and development efforts on the application of precision medicine to the treatment of heritable cardiovascular diseases, and our future success depends on the successful development of products based on our precision medicine platform and the continued development of this platform. We believe we are the first company to apply precision medicine to the treatment of cardiovascular disease, and neither we nor any other company has received regulatory approval to market therapeutics specifically targeting any form of heritable cardiomyopathy. The scientific discoveries that form the basis for our efforts to discover and develop product candidates are novel, and the scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. If we do not successfully develop and commercialize product candidates based upon our technological approach, we will not become profitable and the value of our common stock may decline.

Further, our focus solely on precision medicine for the development of drugs for heritable cardiomyopathies as opposed to multiple, more proven technologies for drug development increases the risks associated with the ownership of our common stock. If we are not successful in developing any product candidates using our precision medicine platform, we may be required to change the scope and direction of our product development activities. In that case, we may not be able to identify and implement successfully an alternative product development strategy, which would materially and adversely affect our business, financial condition and results of operations.

We depend heavily on the success of MYK-461, our lead product candidate. Other than MYK-461, all of our other programs are in discovery or preclinical development. Preclinical testing and clinical trials of our product candidates may not be successful. If we are unable to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.

We have invested a significant portion of our efforts and financial resources in the identification of our lead product candidate, MYK-461, for the treatment of hypertrophic cardiomyopathy (“HCM”). We are currently evaluating MYK-461 in early-stage clinical trials for HCM, and, if MYK-461 fails to demonstrate safety or efficacy to the satisfaction of the FDA or other comparable regulatory authorities, we will need to identify and rely on other product candidates or target indications, or both, for clinical development. All of our other programs are still in discovery or preclinical development. Our ability to generate revenue from product sales, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of MYK-461 or other product candidates that we may identify from our precision medicine platform.

The success of MYK-461 and any other product candidates that we discover and develop will depend on many factors, including the following:

successful enrollment in, and completion of, clinical trials;

receipt of marketing approvals from applicable regulatory authorities;

establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;

obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our medicines;

launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;

acceptance of our products, if and when approved, by patients, the medical community and third-party payors;

effectively competing with other therapies;

a continued acceptable safety profile of our products following approval;

enforcing and defending intellectual property rights and claims; and

achieving desirable medicinal properties for the intended indications.

If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business.

Preclinical and clinical drug development involves a lengthy and expensive process with an uncertain outcome, and observations and results from earlier studies and trials may not be applicable or predictive in future clinical trials.

Preclinical and clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the preclinical development or clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. For example, although our preclinical observations and initial data from two of our Phase 1 clinical trials of MYK-461 support our hypothesis that MYK-461 has the potential to reduce cardiac muscle contractility and our belief that such data have demonstrated clinical proof of mechanism in both HCM patients and healthy volunteers, we have not completed clinical trials of MYK-461 in larger populations. In addition, our precision medicine platform is based on a translational medicine approach. Translational medicine, or the application of basic scientific findings to develop therapeutics that promote human health, is subject to a number of inherent risks. In particular, scientific hypotheses formed from preclinical or early clinical observations may prove to be incorrect, and the data generated in animal models or observed in limited patient populations may be of limited value, and may not be applicable in clinical trials conducted under the controlled conditions required by applicable regulatory requirements and our protocols. For example, although MYK-461 has been observed to reduce cardiac contractility as measured by certain established biomarkers in our first Phase 1 clinical trial in healthy volunteers, the predictive value of these biomarkers in HCM patients may prove to be less than anticipated in subsequent, larger clinical trials. The initial clinical data from our Phase 1 clinical trials of MYK-461 are preliminary in nature, based on limited doses and a small sample size, and the clinical development of MYK-461 is not complete. Early positive data may not be repeated or observed in ongoing or future trials involving our product candidates. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. There is a high failure rate for drugs and biologics proceeding through clinical trials, particularly in the field of cardiovascular medicine. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks in our clinical development could have a material adverse effect on our business and operating results.

We may not be successful in our efforts to identify or discover potential product candidates.

The success of our business depends primarily upon our ability to identify, develop and commercialize therapeutics for the treatment of genetic cardiovascular diseases based on our precision medicine approach. A key element of our strategy is to use our precision medicine platform to identify and study compounds that can be used to correct or offset the abnormal contraction caused by HCM and dilated cardiomyopathy (“DCM”). Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:

the research methodology used may not be successful in identifying appropriate biomarkers or potential product candidates;

our initial hypotheses based on our preclinical or early clinical observations may not be supported by later clinical results;

potential product candidates may, on further study, be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval; or

research programs to identify new product candidates require substantial technical, financial and human resources. We may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful.

If we are unable to identify suitable compounds for preclinical and clinical development, we may be forced to abandon our development efforts for a research program or programs and we will not be able to obtain product revenues in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price.

We may not be able to successfully use the Sarcomeric Human Cardiomyopathy Registry, or SHaRe, to identify or recruit patients for our clinical trials or to develop targeted precision therapeutics for the treatment of heritable cardiomyopathies.

We rely, and expect to continue to rely, on genetic and clinical data gathered through SHaRe to provide us with insight into risk profiles and disease progression in heritable cardiomyopathies. Although the body of information in SHaRe is growing, we may face challenges collecting additional data through SHaRe in the future for a variety of reasons, including:

insufficient funding to support the research necessary to generate patient data for SHaRe;

our failure to maintain existing relationships and establish new relationships with clinical investigators and research institutions whose activities support SHaRe and provide us with access patient data;

our failure to maintain or increase interest in SHaRe within our target patient communities; and

third parties may generate competing databases to which we do not have access.

Additionally, the predictive value of the information generated through SHaRe to date may be limited. Although we expect to use this data to define and identify patient subgroups most likely to respond to our product candidates, our initial hypotheses regarding this data may prove to be incorrect, or our patient selection strategies based on our analysis of this data may fail to yield suitable patients for evaluation in our clinical trials or suitable indications and product candidates for clinical development.

We may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.

Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Although we have clinical trials ongoing for MYK-461, and although we are planning to initiate clinical trials for additional product candidates, we may experience delays in our ongoing clinical trials and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Additionally, we believe that our precision medicine approach should eliminate the need for MYK-461 to undergo the large outcomes-based studies that are often required for cardiovascular drugs as a condition to regulatory approval by the FDA or other regulatory authorities. However, regulatory authorities may nevertheless require us to conduct additional trials or generate additional data, including potential trials studying the interaction of our product candidates with other therapeutics commonly administered in the patient populations we are seeking to treat, which would increase the time and cost of our clinical development process.

Clinical trials can be delayed for a variety of reasons, including:

delays in reaching a consensus with regulatory agencies on trial design;

delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;

delays in obtaining required Institutional Review Board (“IRB”) approval at each clinical trial site;

delays in recruiting suitable patients to participate in our clinical trials;

imposition of a clinical hold by regulatory agencies, after an inspection of our clinical trial operations or trial sites;

failure by our CROs, other third parties or us to adhere to clinical trial requirements;

failure by us or our CROs or other third-party contractors to perform clinical trials in accordance with the FDA’s good clinical practice (“GCP”) requirements or applicable regulatory guidelines in other countries;

delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites;

delays in having patients complete participation in a study or return for post-treatment follow-up;

clinical trial sites deviating from a trial protocol or dropping out of a trial;

clinical trial subjects failing to comply with the trial regimen or dropping out of a trial;

adding new clinical trial sites;

failure to manufacture or supply sufficient quantities of product candidates for use in clinical trials;

occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits; or

changes in regulatory requirements and guidance that require amending or submitting new clinical protocols.

We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, or suspension or termination is recommended by the Data Safety Monitoring Board (“DSMB”) for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.

Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.

If the results of our clinical trials are inconclusive or if there are safety concerns or adverse events associated with our product candidates, we may:

be delayed in obtaining marketing approval for our product candidates, if at all;

obtain approval for indications or patient populations that are not as broad as intended or desired;

obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;

be subject to changes in the way the product is administered;

be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;

have regulatory authorities withdraw their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy (“REMS”);

be subject to the addition of labeling statements, such as warnings or contraindications;

be sued; or

experience damage to our reputation.

We may find it difficult to enroll patients in our clinical trials, which could delay or prevent clinical trials of our product candidates.

Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing to commence and complete our clinical trials depends on the speed at which we can recruit patients to participate in testing our product candidates. If patients are unwilling to participate in our clinical trials because of a lack of familiarity with our approach to the treatment of cardiovascular diseases, negative publicity from adverse events in biotechnology or the fields of precision medicine or cardiovascular disease or for other reasons, including competitive clinical trials for similar patient populations, our timelines for recruiting patients, conducting clinical trials and obtaining regulatory approval of potential products may be delayed. These delays could result in increased costs, delays in advancing our product development, delays in testing the effectiveness of our technology or termination of our clinical trials altogether.

We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics to achieve diversity in a study, to complete our clinical trials in a timely manner. Patient enrollment is affected by factors including:

severity of the disease under investigation;

design of the clinical trial protocol;

size and nature of the patient population;

eligibility criteria for the clinical trial in question;

perceived risks and benefits of the product candidate under study in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;

proximity and availability of clinical trial sites for prospective patients;

availability of competing therapies and clinical trials;

efforts to facilitate timely enrollment in clinical trials;

patient referral practices of physicians; and

ability to monitor patients adequately during and after treatment.

In particular, each of the conditions in which we plan to evaluate our current product candidates is a rare genetic disorder with limited patient pools from which to draw for clinical trials. To date, the HCM and DCM patient populations have not been extensively evaluated in clinical trials. As a result, enrollment in our planned clinical trials is difficult to predict and may take longer or cost more than we anticipate.

We plan to seek initial marketing approval in the United States. We may not be able to initiate or continue clinical trials if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by the FDA or other regulatory agencies. Our ability to successfully initiate, enroll and complete a clinical trial in any foreign country is subject to numerous risks unique to conducting business in foreign countries, including:

difficulty in establishing or managing relationships with CROs and physicians;

different standards for the conduct of clinical trials;

our inability to locate qualified local consultants, physicians and partners; and

the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatment.

If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which would have an adverse effect on our business.

Any of our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval, limit the scope of any approved label or market acceptance or result in other significant negative consequences following marketing approval, if any.

Adverse events or other unintended side effects or safety signals caused by our product candidates could cause us, IRBs or ethics committees, clinical trial sites or regulatory authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval. For example, through additional studies, we may determine that although MYK-461 has been shown to be specific to striated muscle, which includes both skeletal and cardiac muscle, and selective for cardiac muscle, it may target myosin in skeletal muscle, which could result in unintended adverse effects. We have observed a number of adverse events in our Phase 1 clinical trials of MYK-461. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other adverse events in subjects treated with MYK-461. If the adverse events we have observed are deemed to be unacceptable or other unacceptable side effects or safety signals are observed in any ongoing or subsequent preclinical studies or clinical trials of our product candidates, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Any adverse effects encountered in our preclinical studies or clinical trials, whether or not drug-related, could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Additionally, adverse effects may represent safety signals that could influence the benefit-risk assessment for further development or commercialization of a product candidate and may warrant further clinical or nonclinical investigation, consultation with health authorities, changes to product labeling or guidelines for its safe use, or other scientific or regulatory actions. Any of these occurrences may harm our business, financial condition and prospects significantly.

Further, if any of our future products, if and when approved for commercial sale, cause serious or unexpected adverse events, a number of potentially significant negative consequences could result, including:

regulatory authorities may withdraw their approval of the product or impose restrictions on its distribution in the form of a REMS or provide a medication guide outlining the risks of such side effects for distribution to patients;

regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;

we may be required to change the way the product is administered or conduct additional clinical trials;

we could be sued and held liable for harm caused to patients; or

our reputation may suffer.

Any of these events could prevent us or our partners from achieving or maintaining market acceptance of the affected product and could substantially increase the costs of commercializing our future products and impair our ability to generate revenues from the commercialization of these products.

Risks Related to Government Regulation

We currently do not have regulatory approval to market any of our product candidates. The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.

The time required to obtain approval by the FDA, EMA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.

Our product candidates could fail to receive regulatory approval for many reasons, including the following:

the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;

we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;

the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;

we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;

the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;

the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a New Drug Application (“NDA”) or other submission or to obtain regulatory approval in the United States or elsewhere;

the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; or

the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market MYK-461 or any other product candidate we may develop, which would significantly harm our business, results of operations and prospects.

In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.

Even if we complete the necessary preclinical studies and clinical trials, we cannot predict when or if we will obtain regulatory approval to commercialize a product candidate or the approval may be for a more limited indication than we expect.

We cannot commercialize a product until the appropriate regulatory authorities have reviewed and approved the product candidate. Even if our product candidates demonstrate safety and efficacy in clinical trials, the regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials and the review process. Regulatory agencies also may approve a treatment candidate for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our treatment candidates. If we are unable to obtain regulatory approval for our product candidates for use in the treatment of heritable cardiomyopathies, our business may suffer.

Failure to obtain marketing approval in international jurisdictions would prevent our products from being marketed in such jurisdictions.

In order to market and sell our products in the European Union and many other jurisdictions, we or our third-party collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval in other jurisdictions. We may not be able to file for marketing approvals, and even if we do, we may not obtain necessary approvals to commercialize our medicines in any market.

Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.

Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to extensive and ongoing regulatory requirements and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other

post-marketing information and reports, registration and listing requirements, Current Good Manufacturing Practice (“cGMP”) requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. For example, the holder of an approved NDA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process.

In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP and adherence to commitments made in the NDA.

Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine.

The FDA closely regulates the post-approval marketing and promotion of medicines to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers’ communications regarding off-label use and if we do not market our medicines for their approved indications, we may be subject to enforcement action for off-label marketing.

In addition, later discovery of previously unknown problems with our medicines, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in various negative consequences, including:

restrictions on the labeling, marketing or manufacturing of the product;

restrictions on distribution or use of the product;

requirements to conduct post-marketing clinical trials or holds on ongoing or planned clinical trials;

warning or untitled letters;

withdrawal of the medicines from the market;

refusal by the FDA or comparable foreign regulatory authorities to approve pending applications or supplements to approved applications that we submit;

mandatory or voluntary recalls;

fines, restitution or disgorgement of profits or revenue;

suspension or withdrawal of marketing approvals;

refusal to permit the import or export of our medicines;

product seizure or detention; and

injunctions or the imposition of civil or criminal penalties.

The FDA’s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.

Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenues.

We may seek one or more special designations from regulatory authorities for our product candidates, including Breakthrough Therapy Designation, Fast Track Designation or Orphan Drug Designation. These designations may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.

We may seek one or more special designations from regulatory authorities for our product candidates, including Breakthrough Therapy Designation, Fast Track Designation or Orphan Drug Designation.

A breakthrough therapy is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically important endpoints, such as substantial treatment effects observed early in clinical development. For products that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Products designated as breakthrough therapies by the FDA can also be eligible for accelerated approval. If a product is intended for the treatment of a serious or life-threatening condition and the product demonstrates the potential to address unmet medical needs for this condition, the product sponsor may apply for Fast Track Designation.

The FDA has broad discretion whether or not to grant these designations, so even if we believe a particular product candidate is eligible for a particular designation, we cannot assure you that the FDA would decide to grant it. Accordingly, even if we believe one of our product candidates meets the criteria for a designation, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a particular designation for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the products no longer meet the conditions for qualification and rescind the breakthrough designation. Further, the FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from a clinical development program.

Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to incentives such as tax advantages and user-fee waivers. In April 2016, the FDA granted Orphan Drug Designation for MYK-461 for use in the treatment of symptomatic obstructive HCM.

The exclusivity granted under any orphan drug designations that we have received or may receive may not effectively protect the product candidate from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve another drug for the same condition if the FDA concludes that the later drug is clinically superior, in that it is shown to be safer, more effective or makes a major contribution to patient care. Any inability to secure or maintain orphan drug designation or the exclusivity benefits of this designation would have an adverse impact on our ability to develop and commercialize our product candidates.

Risks Related to Our Reliance on Third Parties

We are substantially dependent upon our collaboration agreement with Sanofi for the development and eventual commercialization of MYK-461 and any product candidates from our HCM-2 and DCM-1 programs. If this collaboration is unsuccessful or is terminated, we may be unable to commercialize certain product candidates and we will not receive additional funding from this relationship.

We depend upon our license and collaboration agreement with Aventis Inc., a wholly-owned subsidiary of Sanofi S.A., which we refer to as the Collaboration Agreement, for financial and scientific resources related to the clinical development and commercialization of product candidates under our MYK-461, HCM-2 and DCM-1 programs. While Sanofi has obligations to fund various research and development activities under the collaboration and with respect to the commercialization of product candidates in selected territories under certain programs under the Collaboration Agreement, our ability to receive funding from this relationship will depend upon the ability and willingness of Sanofi to successfully meet its responsibilities under our Collaboration Agreement and continue the collaboration. We may not receive some or all of the financial and scientific resources that we currently expect to receive under our Collaboration Agreement.

Our ability to generate additional funding from our Collaboration Agreement may be impaired by several factors including:

Sanofi may elect not to continue the term of our research collaboration beyond December 31, 2016;

Sanofi may shift its priorities and resources away from our programs due to a change in business strategies, or a merger, acquisition, sale or downsizing of its company or business unit;

Sanofi may cease development and commercialization activities in therapeutic areas which are the subject of our collaboration;

Sanofi may change the success criteria for a particular program or potential product candidate, thereby delaying or ceasing development of such program or candidate;

Sanofi may exercise its rights to terminate the collaboration; or

a dispute may arise between us and Sanofi concerning financial obligations or the research, development or commercialization of a program or product candidate, resulting in a delay in payments or termination of a program and possibly resulting in costly litigation or arbitration which may divert management attention and resources.

Specifically, with respect to termination, the initial term of the research program under our Collaboration Agreement with Sanofi is set to end on December 31, 2018. If, however, prior to December 31, 2016 Sanofi does not provide us with notice of its intent to continue the collaboration or if Sanofi provides notice of its intent to discontinue the collaboration, the research collaboration will terminate on December 31, 2016. Additionally, at any time after December 31, 2018, Sanofi may, upon prior written notice to us, terminate the Collaboration Agreement for convenience in its entirety or on a region-by-region or program-by-program basis with respect to selected regions or programs. The Collaboration Agreement is also subject to termination by either party upon a material breach by the other party, subject to a notice and cure period, or upon a bankruptcy, insolvency or similar event affecting the other party.

If our Collaboration Agreement with Sanofi is terminated, then, depending on the event:

the development of our product candidates subject to the Collaboration Agreement may be terminated or significantly delayed;

our cash expenditures could increase significantly if it is necessary for us to hire additional employees and allocate internal resources to the development and commercialization of product candidates that were previously funded, or expected to be funded, by Sanofi;

we would bear all of the risks and costs related to the further development and commercialization of product candidates that were previously the subject of the Collaboration Agreement;

in order to fund further development and commercialization, we may need to seek out and establish alternative strategic collaborations with third-party partners, which may not be possible; or

we may not be able to do so on terms which are acceptable to us, in which case it may be necessary for us to limit the size or scope of one or more of our programs or increase our expenditures and seek additional funding by other means.

Any of these events would have a material adverse effect on our results of operations and financial condition.

We expect to rely on third parties to conduct some or all aspects of our protocol development, research and preclinical and clinical testing, and these third parties may not perform satisfactorily.

We do not expect to independently conduct all aspects of our protocol development, research and preclinical and clinical testing. We currently rely, and expect to continue to rely, on third parties with respect to these items.

Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it could delay our product development activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations and study protocols. For product candidates that we develop and commercialize on our own, we will remain responsible for ensuring that each of our IND-enabling studies and clinical trials are conducted in accordance with the study plan and protocols. We and our third-party contractors and CROs are required to comply with GCP regulations, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area (“EEA”), and comparable foreign regulatory authorities for all products in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our third-party contractors or CROs fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.

If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will be delayed in completing, or may not be able

to complete, the preclinical and clinical studies required to support future IND submissions and approval of our product candidates. Any of these events could lead to clinical study delays or failure to obtain regulatory approval, or impact our ability to successfully commercialize future products. Some of these events could be the basis for FDA action, including injunction, recall, seizure or total or partial suspension of production.

We contract with third parties for the manufacture of our product candidates for preclinical testing and expect to continue to do so for clinical trials and for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or medicines or that such supply will not be available to us at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.

We do not have any manufacturing facilities. We currently rely, and expect to continue to rely, on third-party manufacturers for the manufacture of our product candidates for preclinical and clinical testing and for the commercial supply of any of these product candidates for which we or our collaborators obtain marketing approval. To date, we have obtained materials for MYK-461 for our Phase 1 clinical trials from third-party manufacturers. We do not have a long term supply agreement with the third-party manufacturers, and we purchase our required drug supply on a purchase order basis. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms.

Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the product candidates ourselves, including:

the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms;

reduced control as a result of using third-party manufacturers for all aspects of manufacturing activities;

reliance on the third party for regulatory compliance, quality assurance, and safety and pharmacovigilance reporting;

the possible breach of the manufacturing agreement by the third party;

the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; and

disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier.

The facilities used by our contract manufacturers to manufacture any of our future products must be approved by the FDA pursuant to inspections that will be conducted after we submit an NDA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the cGMP regulation for manufacture of both active drug substances and finished drug products. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Third-party manufacturers may not be able to comply with cGMP, regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or medicines, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business and results of operations.

Any products that we may develop may compete with our other product candidates and products and the products of third parties for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.

Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for a redundant supply of bulk drug substances. If any one of our current contract manufacturer cannot perform as agreed, we may be required to replace that manufacturer. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement.

Our current and anticipated future dependence upon others for the manufacture of our product candidates or medicines may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis.

Risks Related to Our Intellectual Property

If we are unable to obtain and maintain patent protection for our medicines and technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize medicines and technology similar or identical to ours, and our ability to successfully commercialize our medicines and technology may be adversely affected.

Our commercial success will depend, in part, on our ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary products and technology. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and medicines that are important to our business. To date, we own 2 issued patents that cover our proprietary technology or product candidates. We cannot be certain that we will secure any additional rights to any issued patents with claims that cover any of our proprietary technology or product candidates.

The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

In addition to seeking patents for some of our technology and medicines, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. With respect to our proprietary molecularly targeted small molecule drugs, we consider trade secrets and know-how to be our primary intellectual property. Trade secrets and know-how can be difficult to protect. In particular, we anticipate that with respect to our precision medicine platform, these trade secrets and know-how will over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel skilled in the art from academic to industry scientific positions.

We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be harmed.

Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.

Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter partes reexamination proceedings before the U.S. Patent and Trademark Office, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.

Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties

may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire.

Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all.

Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.

Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.

We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.

Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid, is unenforceable and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.

An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.

We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.

We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. In the future, we may have ownership disputes arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court.

If we or one of our licensing partners initiated legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace.

Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the U.S. PTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection would have a material adverse impact on our business.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.

As is common in the biotechnology and pharmaceutical industry, we employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee’s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

Risks Related to Commercialization and the Market for Our Product Candidates

If the market opportunities for our product candidates are smaller than we believe they are or if we are unable to market our products to expanded patient populations, our revenues may be adversely affected and our business may suffer.

We focus our research and product development efforts on treatments for heritable cardiomyopathies, and our targeted indications are rare genetic diseases. In particular, we estimate that approximately 630,000 people in the United States have a form of HCM, and that approximately 400,000 people in the United States have a form of heritable DCM. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on estimates derived from primary research with physicians and payors, analysis of medical journals and peer-reviewed literature, the work of third-party consultants and other publicly- or non-publicly-available data sources. These estimates may prove to be incorrect and new studies may change the estimated incidence or prevalence of our targeted disease indications. The number of patients in the United States, Europe and elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with our products, and new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business.

Additionally, because the target patient populations of our product candidates are small, we must be able to successfully identify patients and achieve a significant market share to achieve or maintain profitability and growth. Although we plan to use SHaRe to identify and select patients who are suitable for treatment with our products, if approved, we may not be able to identify or target a sufficient number of patients through SHaRe or our sales and marketing efforts to achieve the necessary market share.

Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.

If any of our product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. For example, current cardiovascular disease treatments such as beta blockers, non-dihydropyridine calcium channel blockers and disopyramide are well-established in the medical community, and doctors may continue to rely on these treatments. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:

efficacy and potential advantages compared to alternative treatments;

the ability to offer our medicines for sale at competitive prices;

convenience and ease of administration compared to alternative treatments;

the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;

the strength of marketing and distribution support;

sufficient third-party coverage or reimbursement; and

the prevalence and severity of any side effects.

Any failure to achieve or maintain sufficient market acceptance of MYK-461 or any of our other product candidates, if approved, could significantly harm our business, prospects, financial condition and results of operations.

If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenues.

We have no experience marketing or selling our product candidates. To successfully commercialize any products that may result from our development programs, we will need to develop these capabilities, either on our own or with others. We may enter into collaborations with other entities to utilize their mature marketing and distribution capabilities, but we may be unable to enter into marketing agreements on favorable terms, if at all. If our future collaborations do not commit sufficient resources to commercialize our future products, if any, and we are unable to develop the necessary marketing capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.

The insurance coverage and reimbursement status of newly-approved products targeting small patient populations is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.

The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments, such as endothelin receptor antagonists used in the treatment of certain cardiovascular diseases. Sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. Additionally, therapies directed at small patient populations, such as our product candidates, may be more expensive, and reimbursement options for these therapies may be more limited. If reimbursement or coverage is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.

There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products and for products whose targeted patient populations are small. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare & Medicaid Services (“CMS”), an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. It is difficult to predict what CMS or third-party payors will decide with respect to reimbursement and coverage for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products. Reimbursement agencies in Europe may be more conservative than CMS.

Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries may put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medicines, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits.

Moreover, increasing efforts by governmental and third-party payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in

connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.

Risk Related to Our Business and Industry

We may be subject to healthcare laws, regulation and enforcement, and our failure to comply with these laws could harm our results of operations and financial conditions.

Although we do not currently have any products on the market, if we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations may be directly, or indirectly through our customers and third-party payors, subject to various U.S. federal and state fraud and abuse, patient privacy laws and other healthcare regulatory laws, and to additional healthcare, statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business. Healthcare providers, physicians and others play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. These laws may impact, among other things, our proposed sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers, physicians and other parties through which we market, sell and distribute our products for which we obtain marketing approval. The laws that may affect our ability to operate include:

the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;

the U.S. federal False Claims Act, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;

the U.S. federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) which imposes criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (“HITECH”) and its implementing regulations, and as amended again by the final HIPAA omnibus rule, Modifications to the HIPAA Privacy, Security, Enforcement and Breach Notification Rules Under HITECH and the Genetic Information Nondiscrimination Act; Other Modifications to the HIPAA Rules, published in January 2013, which imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization on covered entities subject to the rule, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information;

the U. S. Federal Food, Drug, and Cosmetic Act (“FDCA”) which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;

the U. S. legislation commonly referred to as the Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, “PPACA”) and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children’s Health Insurance Program to report annually to CMS, information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, as well as ownership and investment interests held by physicians and other healthcare providers and their immediate family members;

analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U. S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug;

manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and

European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers.

Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations.

We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.

Our competitors may develop drugs that are less expensive, safer, or more effective, which may diminish or eliminate the commercial success of any drugs that we may commercialize.

Our competitors may:

develop drug candidates and market drugs that are less expensive or more effective than our future drugs;

commercialize competing drugs before we or our partners can launch any drugs developed from our drug candidates;

initiate or withstand substantial price competition more successfully than we can;

have greater success in recruiting skilled scientific workers from the limited pool of available talent;

more effectively negotiate third-party licenses and strategic collaborations; and

take advantage of acquisition or other opportunities more readily than we can.

We will compete for market share against large pharmaceutical and biotechnology companies and smaller companies that are collaborating with larger pharmaceutical companies, new companies, academic institutions, government agencies and other public and private research organizations. Many of these competitors, either alone or together with their partners, may develop new drug candidates that will compete with ours, as these competitors may, and in certain cases do, operate larger research and development programs or have substantially greater financial resources than we do. Our competitors may also have significantly greater experience in:

developing product candidates;

undertaking preclinical testing and clinical trials;

building relationships with key customers and opinion-leading physicians;

obtaining and maintaining FDA and other regulatory approvals of product candidates;

formulating and manufacturing drugs; and

launching, marketing and selling drugs.

If our competitors market drugs that are less expensive, safer or more effective than our potential drugs, or that reach the market sooner than our potential drugs, we may not achieve commercial success. In addition, the life sciences industry is characterized by rapid technological change. Because our research approach integrates many technologies, it may be difficult for us to stay abreast of the rapid changes in each technology. If we fail to stay at the forefront of technological change we may be unable to compete effectively. Our competitors may render our technologies obsolete by advances in existing technological approaches or the development of new or different approaches, potentially eliminating the advantages in our drug discovery process that we believe we derive from our research approach and proprietary technologies.

Public opinion and heightened regulatory scrutiny of precision medicine for the treatment of cardiovascular disease may impact public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.

Precision medicine remains a novel technology, particularly in the field of cardiovascular disease, with no products approved to date in the United States that are specifically targeted at correcting the underlying biomechanical defects in cardiac contractility associated with HCM and DCM. Public perception may be influenced by claims that these therapies are unproven or unsafe, and our product candidates may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians, who specialize in the treatment of those diseases that our product candidates target, prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments they are already familiar with and for which greater clinical data may be available. More restrictive government regulations or negative public opinion could have an adverse effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Adverse events in our clinical trials, even if not ultimately attributable to our product candidates, and the resulting publicity, could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates.

Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.

In the United States, the EU, and other foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, PPACA changes the way healthcare is financed by both governmental and private insurers and significantly impacts the U.S. pharmaceutical and biotechnology industries. PPACA, among other things, subjects biologic products to potential competition by lower-cost biosimilars, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs and biologic agents, and a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D. At this time, the full effect that PPACA would have on our business remains unclear.

In addition, other legislative changes have been proposed and adopted in the United States since PPACA was enacted. On August 2, 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2024 unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other health care funding, which could have a material adverse effect on our customers and accordingly, our financial operations.

Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. The U.S. federal government has set a goal of moving 50% of Medicare payments into these “Alternative Payment Models” by the end of 2018. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.

Our future success depends on our ability to retain key employees and consultants, including our scientific advisors and founders, and to attract, retain and motivate qualified personnel.

We are highly dependent on our scientific advisors and founders and the principal members of our executive team, the loss of whose services may adversely impact the achievement of our objectives. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time, as all of our employees are “at will” employees. Recruiting and retaining other qualified employees, consultants and advisors for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled executives and scientific experts in our industry, which is likely to continue. As a result, competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies, as well as from academic and research institutions, for individuals with similar skill sets. In addition, any failure of our programs to succeed in preclinical studies or clinical trials may make it more challenging to recruit and retain qualified personnel. The inability to recruit or the loss of the services of any executive, key employee, consultant or advisor may impede the progress of our research, development and commercialization objectives.

We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations.

As of March 31, 2016, we had 63 full-time employees. As we mature, we expect to expand our full-time employee base and to hire more consultants and contractors. Our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.

We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial medicines or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable medicines. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.

Our anticipated international operations may expose us to business, regulatory, political, operational, financial, pricing and reimbursement and economic risks associated with doing business outside of the United States.

We have a wholly-owned Australian subsidiary through which we conduct clinical trials in Australia. Our business strategy also contemplates potential additional international operations as we seek to continue the development of MYK-461 and other product candidates that we have or may identify, seek regulatory approval for our product candidates, and commercialize any product candidates that are approved outside the United States. If any product candidates for which we have retained worldwide commercial rights are approved, we may hire sales representatives and conduct physician and patient group outreach activities outside of the United States. Doing business internationally involves a number of risks, including but not limited to:

multiple, conflicting, and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements, and other governmental approvals, permits, and licenses;

failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;

complexities and difficulties in obtaining protection for and enforcing our intellectual property rights;

difficulties in staffing and managing foreign operations;

complexities associated with managing multiple payor reimbursement regimes, government payors, or patient self-pay systems;

limits in our ability to penetrate international markets;

financial risks, such as exposure to foreign currency exchange rate fluctuations and their impact on payments required in local currency;

natural disasters, political and economic instability, including wars, terrorism, and political unrest, outbreak of disease, boycotts, curtailment of trade, and other business restrictions;

certain expenses including, among others, expenses for travel, translation, and insurance; and

regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions, or its anti-bribery provisions.

Any of these factors could significantly harm our future international expansion and operations and, consequently, our results of operations.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.

We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.

Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

Our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaboration partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.

We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaboration partners may engage in fraudulent conduct or other illegal activities. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate: (i) the regulations of the FDA, EMA and other regulatory authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; (ii) manufacturing standards; (iii) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad; or (iv) laws that require the reporting of true, complete and accurate financial information and data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent misconduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other U.S. federal

healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.

Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets upon which biopharmaceutical companies such as us are dependent for sources of capital. In the past, global financial crises have caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as the recent global financial crisis, could result in a variety of risks to our business, including a reduced ability to raise additional capital when needed on acceptable terms, if at all, and weakened demand for our product candidates. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.

We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.

Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.

Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any medicines that we may develop.

We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any medicines that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or medicines caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:

decreased demand for any product candidates or medicines that we may develop;

injury to our reputation and significant negative media attention;

withdrawal of clinical trial participants;

significant costs to defend the related litigation;

substantial monetary awards to trial participants or patients;

loss of revenue; and

the inability to commercialize MYK-461 or any other product candidates that we may develop.

Although we maintain product liability insurance, including coverage for clinical trials that we sponsor, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as we commence additional clinical trials and if we successfully commercialize any product candidates. The market for insurance coverage is increasingly expensive, and the costs of insurance coverage will increase as our clinical programs increase in size. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.

Our internal computer systems, or those of our third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our operations.

Despite the implementation of security measures, our internal computer systems and those of our third-party CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For example, the loss of clinical trial data for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of

or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and experience delays or disruptions to various aspects of our operations, including our financial reporting and the development of our product candidates.

Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.

We have incurred substantial losses during our history and do not expect to become profitable in the near future. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the “Code”) if a corporation undergoes an “ownership change,” generally defined as a greater than 50 percentage point change (by value) in its equity ownership over a rolling three-year period, the corporation’s ability to use its pre-change net operating loss carryforwards (“NOLs”) and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. While we have determined that an ownership change occurred in April 2015 in connection with our Series B redeemable convertible preferred stock financing, we do not believe that this ownership change will result in the expiration of any of our existing NOLs prior to utilization. We may experience subsequent shifts in our stock ownership, some of which are outside our control. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.

Risk Related to Our Common Stock

The market price of our common stock has been and may continue to be highly volatile.

The market price of our common stock has experienced volatility since our IPO in October 2015 and is likely to continue to be volatile. Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:

adverse results or delays in preclinical studies or clinical trials;

reports of adverse events in other products for the treatment of cardiovascular diseases or clinical trials of such products;

a decision by Sanofi to terminate or cease moving forward with the Collaboration Agreement;

inability to obtain additional funding;

any delay in filing an IND or NDA for any of our product candidates and any adverse development or perceived adverse development with respect to the FDA’s review of that IND or NDA;

failure to develop successfully and commercialize our product candidates;

failure to maintain our existing strategic collaborations or enter into new collaborations;

failure by us or our licensors and strategic collaborators to prosecute, maintain or enforce our intellectual property rights;

changes in laws or regulations applicable to future products;

inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices;

adverse regulatory decisions affecting our product candidates or development programs;

introduction of new products, services or technologies by our competitors;

failure to meet or exceed financial projections we may provide to the public or to the investment community;

the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;

announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic collaboration partner or our competitors;

disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;

additions or departures of key scientific or management personnel;

significant lawsuits, including patent or stockholder litigation;

changes in the market valuations of similar companies;

sales of our common stock by us or our stockholders in the future; and

trading volume of our common stock.

In addition, companies trading in the stock market in general, and The NASDAQ Global Select Market (“NASDAQ”) in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if instituted against us, could result in substantial costs and diversion of management’s attention and resources, which could materially and adversely affect our business, financial condition, results of operations and growth prospects.

Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.

Additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.

In addition, sales of a substantial number of shares of our outstanding common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. The lock-up agreements pertaining to our IPO expired on April 26, 2016. As a result, persons who were our stockholders prior to our IPO continue to hold a substantial number of shares of our common stock that many of them are now able to sell in the public market. Significant portions of these shares are held by a relatively small number of stockholders. Sales by our stockholders of a substantial number of shares, or the expectation that such sales may occur, could significantly reduce the market price of our common stock.

We have also registered all shares of our common stock subject to options or other equity awards issued or reserved for future issuance under our equity incentive plans. As a result, these shares will be eligible for sale in the public market to the extent permitted by any applicable vesting requirements and the exercise of options, and restrictions under applicable securities laws. Moreover, certain holders of our common stock have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. If we were to register the resale of these shares, they could be freely sold in the public market. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.

Pursuant to our 2015 Stock Option and Incentive Plan (the “2015 Plan”), we are authorized to grant stock options and other equity-based awards to our employees, directors and consultants. Beginning on January 1, 2017, the number of shares available for future grant under the 2015 Plan will automatically increase each year by up to 4% of all shares of our capital stock outstanding as of December 31 of the prior calendar year, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. In addition, pursuant to our 2015 Employee Stock Purchase Plan (the “2015 ESPP”), we have initially reserved 255,000 shares for purchase by eligible employees. Beginning on January 1, 2017 and ending on January 1, 2025, the number of shares available for future issuance under the 2015 ESPP will automatically increase each year by up to the lesser of 3,000,000 shares of common stock or 1% of all shares of our capital stock outstanding as of December 31 of the prior calendar year, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. Currently, we plan to register the increased number of shares available for issuance under the 2015 Plan and the 2015 ESPP each year. If our board of directors elects to increase the number of shares available for future grant under these plans by the maximum amount each year, our stockholders may experience additional dilution, which could cause our stock price to fall.

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

As of May 5, 2016, our executive officers, directors, five percent or greater stockholders and their affiliates beneficially own approximately 78.3% of our outstanding voting stock. These stockholders will have the ability to influence us through their ownership positions. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of our organizational documents, or approval

of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders.

We have broad discretion in the use of our cash and cash equivalents and may not use them effectively.

Our management has broad discretion in the application of our existing cash and cash equivalents, and you will not have the opportunity to assess whether our existing cash and cash equivalents are being used appropriately. Because of the number and variability of factors that will determine our use of our existing cash and cash equivalents, their ultimate use may vary substantially from their currently intended use. The failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest our cash and cash equivalents in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders.

If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline.

The trading market for our common stock will depend, in part, on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts may not publish an adequate amount of research on our company, which may negatively impact the trading price for our stock. In addition, if one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. Further, if our operating results fail to meet the forecasts of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.

We are an “emerging growth company,” and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.

We are an “emerging growth company,” as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We will remain an emerging growth company until the earliest of (i) December 31, 2020, (ii) the last day of the fiscal year in which we have total annual gross revenue of $1.0 billion or more, (iii) the last day of the fiscal year in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30^th and (iv) the date on which we have issued more than $1.0 billion in non-convertible debt during any three-year period before that time. Even after we no longer qualify as an emerging growth company, we may still qualify as a “smaller reporting company” which would allow us to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act (“Section 404”), and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, are subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

We will continue to incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.

As a public company, and particularly after we are no longer an emerging growth company, we incur and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the SEC and NASDAQ have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance.

Pursuant to Section 404, we will be required to furnish a report by our management on our internal control over financial reporting starting with our 2016 Annual Report on Form 10-K and an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an emerging growth company, we will not be required to obtain an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting.

Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could impair our ability to produce timely and accurate consolidated financial statements and result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our consolidated financial statements.

Our operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.

Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult to predict our future operating results. Our net loss and other operating results will be affected by numerous factors, many of which are outside of our control and may be difficult to predict, including:

variations in the level of expenses related to our precision medicine platform, our product candidates or our research and development programs;

the timing and success or failure of preclinical studies and clinical trials for our product candidates or competing product candidates;

our ability to obtain regulatory approval for our product candidates, and the timing and scope of any such approvals we may receive;

if any of our product candidates receives regulatory approval, the level of underlying demand for these product candidates;

addition or termination of clinical trials or funding support;

our execution of any new collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements.

any intellectual property infringement or other lawsuits in which we may become involved; and

regulatory developments affecting our product candidates or those of our competitors.

If our operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. Additionally, due to the unpredictability of our quarterly and annual operating results, we believe that period-to-period comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.

Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.

We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.

We could be subject to securities class action litigation.

In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management.

Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that may have the effect of delaying or preventing a change in control of us or changes in our management. Our amended and restated certificate of incorporation and amended and restated bylaws include provisions that:

authorize “blank check” preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock;

create a classified board of directors whose members serve staggered three-year terms;

specify that special meetings of our stockholders can be called only by our board of directors, the chairperson of our board of directors, our chief executive officer or our president;

prohibit stockholder action by written consent;

establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;

provide that our directors may be removed only for cause and with the vote of the holders of 75% or more of our outstanding capital stock then entitled to vote at an election of directors;

provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even if less than a quorum;

specify that no stockholder is permitted to cumulate votes at any election of directors;

expressly authorize our board of directors to modify, alter or repeal our amended and restated bylaws; and

require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated certificate of incorporation and amended and restated bylaws.

These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management.

In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us.

Any provision of our amended and restated certificate of incorporation or amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

(a)

Recent Sales of Unregistered Equity Securities

None.

(b)

Use of Proceeds

Not applicable.

(c)

Issuer Repurchases of Company Equity Securities.

During the three months ended March 31, 2016, we repurchased the following shares of common stock:

	(a) Total Number of Shares (or Units) Purchased ⁽¹⁾		(b) Average Price Paid per Share (or Unit)		(c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs		(d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
Period	(in thousands, except per share amounts)
January 1, 2016 through January 31, 2016		37,074	$	0.82		—		—
February 1, 2016 through February 29, 2016		—	$	—		—		—
March 1, 2016 through March 31, 2016		—	$	—		—		—
Total		37,074	$	0.82		—		—

(1)

Under certain stock purchase agreements with employees, we have the right to repurchase common stock at the lower of fair value and the stockholders' original purchase price, which right lapses according to individual vesting schedules. Reflects shares of common stock repurchased in connection with the termination of services by certain employees.

Item 3.

Defaults Upon Senior Securities

None.

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5.

Other Information

None.

Item 6.

Exhibits

See the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits filed as part of this Quarterly Report on Form 10-Q, which Exhibit Index is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MYOKARDIA, INC.

Date: May 12, 2016		MYOKARDIA, INC.

	By:		/s/ Tassos Gianakakos
			Tassos Gianakakos
			President, Chief Executive Officer
			(principal executive officer)


Date: May 12, 2016	By:		/s/ Steven Chan
			Steven Chan
			Vice President, Corporate Controller
			(principal financial and accounting officer)

EXHIBIT INDEX

Exhibit Number		Exhibit Description	Incorporated by Reference From	Date	Number	Filed Herewith

3.1		Restated Certificate of Incorporation.	10-Q	11/18/2015	3.1

3.2		Amended and Restated Bylaws.	S-1/A	10/13/2015	3.4

4.1		Specimen Common Stock Certificate	S-1/A	10/19/2015	4.1

10.1#		Senior Executive Cash Incentive Bonus Plan	8-K	2/5/2016	10.1

10.2#		Transitional Services Agreement, dated February 18, 2016, by and between MyoKardia, Inc. and Jonathan C. Fox, M.D., Ph.D.				X

31.1		Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.				X

31.2		Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.				X

32.1*		Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350.				X

101.INS		XBRL Instance Document.				X

101.SCH		XBRL Taxonomy Extension Schema Document.				X

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document				X

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document				X

101.LAB		XBRL Taxonomy Extension Label Linkbase Document				X

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document				X

#	Represents management compensation plan, contract or arrangement.

The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of MyoKardia, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

EX-10.2 2 myok-ex102_242.htm EX-10.2 myok-ex102_242.htm

Exhibit 10.2

February 17, 2016

Jonathan C. Fox, M.D., Ph.D.

1788 Clay Street Ste809

San Francisco, CA 94109

Re: Transitional Services Agreement

Dear Jonathan:

This letter follows our recent discussions and proposes a mutual and amicable agreement (the “Agreement”) regarding your transition from employment with MyoKardia, Inc. (the “Company”). We appreciate your contributions and would like to work with you to make this transition as smooth as possible. With that in mind, this Agreement proposes an amicable arrangement under which you would be eligible to continue to be employed at the Company during a transition period, receive severance after the transition period, and be paid to provide post-employment consulting services.

If signed and not revoked, this Agreement will become a binding agreement between you and the Company (the “Agreement”) as of the Effective Date (as defined in Section 22 below) and will fully supersede other agreements or understanding between you and the Company relating to severance pay and benefits, including, without limitation, the employment offer letter dated March 4, 2013 (the “Offer Letter”). However, regardless of whether you enter into this Agreement, your obligations under the Employee Confidentiality and Assignment Agreement signed by you on August 29, 2013 (the “NDA”) shall continue to be in full force and effect. A true and correct executed copy of said NDA is attached hereto as Exhibit A and incorporated herein by reference.

The actual last day of your employment (whether it is, as described further in Section 1, on September 30, 2016 or on an earlier date) shall be referred to as the “Separation Date” and the time period between the Effective Date and the Separation Date shall be referred to as the “Transition Period.”

With those understandings, the Agreement between you and the Company is as follows:

1.	Titles/Duties During Transition Period

The Company will continue to employ you on an at-will basis through the Transition Period. Although you will be an at-will employee, if you are terminated without Cause or if you resign for Good Reason (both as defined herein), you will be entitled to additional payments from the Company, as set forth in Section 5 below, subject to the terms and conditions of this Agreement. Your job title during the Transition Period shall remain Chief Medical Officer (“CMO”) unless and until the Company hires a new Chief Medical Officer, at which time your job title shall become Senior Advisor for the duration of the Transition Period. You will continue to work and provide services to the Company on a regular full-time basis during the Transition Period. Your duties during the Transition Period, as well as the location where you will perform services and

Jonathan C. Fox, M.D., Ph.D.

February 17, 2016

Page 2

other details associated with your employment during the Transition Period will be determined and communicated to you by the Company’s Chief Executive Officer (“CEO”). Your job duties will include performing the CMO role until the new Chief Medical Officer (“New CMO”) is hired by the Company and transitioning information to other employees of the Company, including the New CMO. As a Senior Advisor you will perform executive-level duties as requested by the Company.

The Separation Date will be the earliest of the following:

(a)

September 30, 2016;

(b)

The date of your voluntary resignation from the Company;

(c)

The date the Company terminates your employment without Cause;

(d)

The date the Company terminates your employment for “Cause;”¹ or

(e)

The date that you resign for “Good Reason”.²

In the interest of clarity, the ending of your employment prior to September 30, 2016 will accelerate your Separation Date but, except for a termination pursuant to 1(b) or 1(d), such early termination will not preclude you from receiving the Severance Benefits described in Section 5 so long as you are otherwise in compliance with the terms of this Agreement. If your employment ends due your voluntary resignation before September 30, 2016 without the Company’s prior consent or due to a termination for Cause, you will be paid through the Separation Date but you will not be entitled to the Severance Benefits or to the benefits of the Consulting Agreement (as described below).

2.	Compensation Transition Period

You shall continue to receive your full base salary at the annual rate of $370,250.00 (the “Base Salary Rate”) and benefits as a regular full-time employee during the Transition Period. The Base Salary Rate shall not be increased or decreased during the Transition Period or the Salary

For purposes of this Agreement, “Cause” shall mean your (i) dishonesty, embezzlement, misappropriation of assets or property of the Company; (ii) gross negligence, misconduct, neglect of duties, theft, fraud, or breach of fiduciary duty to the Company; (iii) violation of federal or state securities laws; (iv) a material breach of this Agreement which, if curable, remains uncured after written notice and 30 days opportunity to cure; (v) the conviction of a felony, or any crime involving moral turpitude, including a plea of guilty or nolo contendre; or (vi) material unsatisfactory performance as determined by the Board of Directors of the Company after written notice and a thirty (30) day opportunity to cure.

For the purposes of this Agreement, “Good Reason” means your resignation within thirty (30) days following any action by the Company (or its successor or acquirer) which: (i) reduces the Base Salary Rate or Target Bonus prior to the Separation Date; (ii) relocates Employee’s regular work site more than twenty-five (25) miles without his consent; or (iii) unilaterally change Employee’s title, other than as contemplated by this Agreement. Before resigning for Good Reason, Employee shall provide Company thirty days written notice and an opportunity to cure.

Jonathan C. Fox, M.D., Ph.D.

February 17, 2016

Page 3

Continuation Period. You may also be eligible for a 2016 bonus subject to Section 5(c) of this Agreement. At the end of the Transition Period, the Company agrees to pay you accrued and unused vacation time to the extent required under California law.

3.	Conditions; Consulting Agreement

Provided that (a) this Agreement becomes effective upon signature by both parties, (b) you are not separated from the Company as a result of your voluntary resignation or the Company terminating your employment with Cause; and (c) you complete the Follow-On Release attached hereto as Exhibit B on or after the Separation Date (the “Conditions”), then immediately after the Separation Date, the consulting agreement attached hereto as Exhibit C (the “Consulting Agreement”) will become effective and shall govern the post-employment relationship between you and the Company, pursuant to which the Company will pay you an hourly fee for any services the Company asks you to provide from the Separation Date through the earliest of March 31, 2017 or the date the Consulting Agreement is sooner terminated by you or by the Company (but, for the avoidance of doubt, the Company may only terminate the Consulting Period prior to March 31, 2017 for Cause) in accordance with its terms (the “Consulting Period”). For the avoidance of doubt, if any of the Conditions are not satisfied, your relationship with the Company will end on the Separation Date and the Consulting Agreement will be null and void. As described in greater detail in the Consulting Agreement, during the Consulting Period, you will no longer be an employee of the Company, but instead will be retained as an independent contractor.

4.	Equity Vesting

During the Transition Period and, and subject to Section 3, during the Consulting Period you shall continue to vest in the stock option grant made to you on March 13, 2013 consistent with the terms and conditions of the Stock Option Grant Notice dated March 13, 2013 (the “Stock Agreement”) and the Company’s 2012 Equity Incentive Plan (the “Plan” and, together with the Stock Agreement, the “Equity Documents. With respect to the separate stock option grant made to you on June 4, 2015, you acknowledge and agree that you will not be entitled to vest in any portion of such stock option grant. Accordingly, the entirety of the stock option granted to you on June 4, 2015 will lapse on the Separation Date and will not be exercisable by you.

Jonathan C. Fox, M.D., Ph.D.

February 17, 2016

Page 4

5.	Severance Benefits

Provided that each of the Conditions have been satisfied, the Company will provide you with the following Severance Benefits:

(a) Salary Continuation. For the period from the Separation Date until June 30, 2017 (the “Salary Continuation Period”), you will receive salary continuation based on the Base Salary Rate, from which all applicable federal, state and local taxes and withholdings will be deducted.

(b) Continuation of Medical and Dental Benefits. To the extent that you are eligible to continue to participate in our medical and dental plans under COBRA and you elect to continue such benefits, the Company will pay your COBRA premiums during the Salary Continuation Period.

(c) 2016 Bonus: To the extent that all of the pre-established performance milestones (“Milestones”) associated with your 2016 bonus are achieved, you will be entitled to receive an amount equal to 100% of your 2016 bonus target of $100,000.00 (the “2016 Target Bonus”). You may earn part of the 2016 Target Bonus based on your achievement of some of the Milestones, as determined by the Company in its reasonable good faith discretion. If earned in all or in part, the 2016 Bonus shall be payable at the time 2016 bonuses are paid to other Company employees but in no event later than March 15, 2017. The parties acknowledge and agree that the Milestones associated percentages with respect to the 2016 Target Bonus will be set forth in a separate written notice to you.

6.	Return of Property

You shall not dispose of Company property (including information or documents, including computerized data Company and any copies made of any computerized data Company or software (“Documents”), without authorization. You agree to return as soon as possible on the Separation Date to the Company all Company property, including, without limitation, computer equipment, software, keys and access cards, credit cards, files and any Documents containing information concerning the Company, its business or its business relationships (in the latter two cases, actual or prospective) and any information about the Company’s sales strategies and mechanics associated with implementing those strategies, unless the Company notifies you that you may retain such property in order to provide consulting services during the Consulting Period. After returning all Documents and Company property, you commit to deleting and finally purging any duplicates of files or documents that may contain Company information from any non-Company computer or other device that remains your property, unless the Company notifies you that you may retain such property in order to provide consulting services during the Consulting Period. In the event that you discover that you continue to retain any such property, you shall return it to the Company immediately, unless the Company notifies you that you may retain such property in order to provide consulting services during the Consulting Period (as defined below).

Jonathan C. Fox, M.D., Ph.D.

February 17, 2016

Page 5

7.	Trade Secrets; Confidential Information

You understand and agree that you have been employed in a position of confidence and trust and have had access to information concerning the Company that the Company treats as confidential and the disclosure of which could negatively affect the Company’s interests (such information referred to herein as “Proprietary Information” as such term is defined in the NDA). You reaffirm and agree to observe and abide by the terms of the NDA, specifically including the provisions therein regarding: nondisclosure of the Company’s trade secrets and confidential and proprietary information, nonsolicitation of Company employees, and noncompetition and nonsolicitation of customers to the extent enforceable under applicable law. You acknowledge that during the course of your employment with the Company you have accessed a number of highly confidential materials including materials concerning the Company’s business, technology, business relationships or financial affairs all of which is “Proprietary Information” under the NDA and you specifically represent that you shall refrain from directly or indirectly disclosing or using any such Proprietary Information in the future including in connection with any business activities. If it is determined by an arbitrator pursuant to Section 19(a) or a court of competent jurisdiction pursuant to Section 19(c) that you violated this or any other restriction in the NDA, in addition to all other legal and equitable remedies that the Company may have it shall be entitled to recover its reasonable attorney’s fees associated with enforcing the NDA.

8.	Future Cooperation

You agree to cooperate reasonably with the Company (including its outside counsel) in connection with the contemplation, prosecution and defense of all phases of existing, past and future litigation about which the Company believes you may have knowledge or information. You agree to make yourself available during and outside of regular business hours for such cooperation; provided that the Company shall not utilize this paragraph to require you to make yourself available to an extent that would unreasonably interfere with your search for employment or any subsequent employment responsibilities that you may have. You agree to appear without the necessity of a subpoena to testify truthfully in any legal proceedings in which the Company calls you as a witness. In connection with fulfilling your obligations under this Section 8, your pre-approved, out of pocket and reasonable expenses will be reimbursed by the Company, and you will also be entitled to be compensated at the hourly rate of $450 for any hours over and above ten (10) hours that you are required to spend on such cooperation after the ending of the Consulting Period and the Salary Continuation Period. During the Consulting period you shall be entitled to bill for time spent in cooperating with the Company.

9.	Non-Disparagement

You agree not to make any disparaging statements concerning the Company or any of its affiliates or its or their products or services, or its or their current or former officers, directors, shareholders, or employees. For the avoidance of doubt, nothing in this Agreement shall be interpreted or applied to prohibit you from making any good faith report to any governmental agency or other governmental entity concerning any act or omission that you reasonably believe constitutes a possible violation of federal or state law or making other disclosures that are protected under the anti-retaliation or whistleblower provisions of applicable federal or state law

Jonathan C. Fox, M.D., Ph.D.

February 17, 2016

Page 6

or regulation. At the end of the Transition Period, the Company will instruct members of its senior executive team and members of the Company’s Board that they should not make any disparaging comments about you.

10.	Communications Regarding Your Departure

You will not reveal your transition and/or departure to anyone other than your immediate family or legal counsel until the Company has issued a written announcement that you will have any opportunity to review and comment on prior to its issuance. Such communication will state that you will be transitioning from your role as the Company’s CMO and that the Company has undertaken a search for a new CMO but that you will continue as CMO until a new CMO is hired and, thereafter, you will continue to support the Company as a Senior Advisor.

11.	Tax Treatment

The Company shall undertake to make deductions, withholdings and tax reports with respect to payments and benefits under this Agreement to the extent that it reasonably and in good faith determines that it is required to make such deductions, withholdings and tax reports. Payments under this Agreement are stated in gross amounts and shall be paid in amounts net of any such deductions or withholdings. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate you for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit.

12.	Release of Your Claims

In consideration for, among other terms, the payments, benefits and opportunities described in this Agreement, and contingent on the receipt by you of same consistent with the terms of this Agreement, you voluntarily release and forever discharge the Company, its affiliated and related entities, its and their respective predecessors, successors and assigns, its and their respective employee benefit plans and fiduciaries of such plans, and the current and former officers, directors, shareholders, employees, attorneys, accountants and agents of each of the foregoing in their official and personal capacities (collectively referred to as the “Releasees”) generally from all claims, demands, debts, damages and liabilities of every name and nature, known or unknown (“Claims”) that, as of the date when you sign this Agreement, you have, ever had, now claim to have or ever claimed to have had against any or all of the Releasees. This release includes, without limitation, all Claims relating to your employment by and the decision to terminate your employment with the Company; of wrongful discharge; of breach of contract; of retaliation or discrimination under federal, state or local law (including, without limitation, Claims of discrimination or retaliation, the Age Discrimination in Employment Act, Americans with Disabilities Act, Title VII of the Civil Rights Act of 1964, the California Fair Employment and Housing Act); under any other federal or state statute (including, without limitation, the Employee Retirement Income Security Act, the Fair Labor Standards Act, the California Family Rights Act, and the Family Medical Leave Act); of defamation or other torts; of violation of public policy; for wages, bonuses, incentive compensation, commissions, stock, stock options, vacation pay or any other compensation or benefits including without limitation, either under the California Labor Code or otherwise; and for damages or other remedies of any sort, including,

Jonathan C. Fox, M.D., Ph.D.

February 17, 2016

Page 7

without limitation, compensatory damages, punitive damages, injunctive relief and attorney’s fees; provided, however, that this release shall not affect your vested rights, if any, under the Company’s 401(k) plan or any of your rights under this Agreement.

13.	California Civil Code Section 1542

You acknowledge that you have been advised to consult with legal counsel and are familiar with the provisions of California Civil Code Section 1542, a statute that otherwise prohibits the release of unknown claims, which provides as follows:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.

You, being aware of said code section, agree to expressly waive any rights you may have thereunder, as well as under any other statute or common law principles of similar effect.

14.	Nonadmission

This Agreement shall not be construed as an admission of any liability by the Company or you of any act of wrongdoing. The Company and you specifically disclaims that it or any of its representatives has engaged in any wrongdoing or has taken any action that would be the basis for any finding of liability.

15.	Legal Representation

This Agreement is a legally binding document and your signature will commit you to its terms. You acknowledge that you have been advised to discuss all aspects of this Agreement with your attorney, that you have in fact done so, that you have carefully read and fully understand all of the provisions of this Agreement, and that you are voluntarily entering into this Agreement.

16.	Absence of Reliance

In signing this Agreement, you are not relying upon any promises or representations made by anyone at or on behalf of the Company, other than those set forth herein.

17.	Enforceability

If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of the NDA) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.

Jonathan C. Fox, M.D., Ph.D.

February 17, 2016

Page 8

18.

Waiver

No waiver of any provision of this Agreement shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.

19.	Enforcement

(a) Arbitration of Disputes. Any controversy or claim arising out of or relating to this Agreement, the NDA, the Consulting Agreement, the Equity Documents or any breach thereof or otherwise arising out of the Executive’s employment or the termination of that employment (including, without limitation, any claims of unlawful employment discrimination) shall, to the fullest extent permitted by law, be settled exclusively by a single arbitrator with significant experience in employment matters in any forum and form agreed upon by the parties or, in the absence of such an agreement, under the auspices of JAMS, Inc. (“JAMS”) in San Francisco, CA in accordance with the JAMS Employment Dispute Resolution Rules of including, but not limited to, the rules and procedures applicable to the selection of the arbitrator. In the event that any person or entity other than you or the Company may be a party with regard to any such controversy or claim, such controversy or claim shall be submitted to arbitration subject to such other person or entity’s agreement, unless arbitration of such other person’s claims is prohibited by law. You will be required to pay an arbitration fee to initiate any arbitration equal to what you would be charged as a first appearance fee in court. The Company shall advance all remaining fees and costs of the arbitrator. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. This Section 19(a) shall be specifically enforceable. The only exception to this Section 19(a) shall be that a party is not precluded from pursuing a court action for the sole purpose of obtaining a temporary restraining order or a preliminary injunction in circumstances in which such relief is appropriate, including as contemplated in Section 19(b); provided that any other relief shall be pursued through an arbitration proceeding pursuant to this Section 19(a).

(b) Relief. You agree that it would be difficult to measure any harm caused to the Company that might result from any material breach by you of your promises set forth in Sections 6, 7, 8, 9 or 10 of this Agreement or in the NDA and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, you agree that if you breach, or propose to breach, any portion of your obligations under this Agreement, the Company shall be entitled, in addition to all other remedies it may have, to an injunction or other appropriate equitable relief to restrain any such breach.

(c) Jurisdiction. Subject to Section 19(a), you and the Company hereby agree that a state court in Santa Clara County, California shall have the exclusive jurisdiction to consider any matters related to your employment and your consulting relationship with the Company. With respect to any such court action, you (i) submit to the jurisdiction of

Jonathan C. Fox, M.D., Ph.D.

February 17, 2016

Page 9

such court, (ii) consent to service of process, and (iii) waive any other requirement (whether imposed by statute, rule of court or otherwise) with respect to personal jurisdiction or venue.

(d) Attorneys’ Fees. In the event of a dispute under this Agreement, the parties agree that the arbitrator or judge shall have the authority to award the prevailing party its attorneys’ fees and costs to the extent authorized by applicable law.

20.	Governing Law; Interpretation

This Agreement shall be interpreted and enforced under the laws of the State of California without regard to conflict of law principles. In the event of any dispute, this Agreement is intended by the parties to be construed as a whole, to be interpreted in accordance with its fair meaning, and not to be construed strictly for or against either you or the Company or the “drafter” of all or any portion of this Agreement.

21.	Section 409A

To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the termination of employment, then such payments or benefits shall be payable only upon your “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A‑1(h). The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A‑2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.

22.	Entire Agreement and Time to Consider

This Agreement along with the NDA, the Consulting Agreement and the Equity Documents constitutes the entire agreement between you and the Company with respect to the subject matter herein. This Agreement supersedes any previous agreements or understandings between you and the Company with respect to the subject matter herein, including, without limitation, the Offer Letter.

Jonathan C. Fox, M.D., Ph.D.

February 17, 2016

Page 10

You acknowledge that you have been given the opportunity, if you so desired, to consider this Agreement for twenty-one (21) days before executing it (the “Consideration Period”). You agree that changes to this Agreement do not restart the Consideration Period. If not signed by you and returned to me so that I receive it within the Consideration Period, this Agreement will not be valid. In addition, if you breach any of the conditions of the Agreement within the Consideration Period, the offer of this Agreement is withdrawn and your execution of the Agreement will not be valid. In the event that you execute and return this Agreement within less than twenty-one (21) days of the date of its delivery to you, you acknowledge that such decision was entirely voluntary and that you had the opportunity to consider this Agreement for the entire twenty-one (21) day period. The Company acknowledges that for a period of seven (7) days from the date of your execution of this Agreement, you shall retain the right to revoke this Agreement by written notice that I receive before the end of such period, and that this Agreement shall not become effective or enforceable until the expiration of such revocation period (the “Effective Date”)

23.	Counterparts

This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original, but all of which together shall constitute one and the same document. Facsimile and pdf signatures shall be deemed to have the same legal effect as originals.

[signature page follows]

By signing below I agree to and accept the terms of this Agreement for the Company. Please indicate your agreement to the terms of this Agreement by signing and returning to me the original of this letter within the Consideration Period.

Very truly yours,

MYOKARDIA, INC.

/s/ Tassos Gianakakos

Tassos Gianakakos

Chief Executive Officer

The foregoing is agreed to and accepted by:

/s/ Jonathan C. Fox, M.D., Ph.D.		18 Feb. 2016
Jonathan C. Fox, M.D., Ph.D.		Date

[Signature Page to Jonathan C. Fox, M.D., Ph.D. Transitional Services Agreement]

EXHIBIT A

[NDA]

EXHIBIT B

FOLLOW-ON RELEASE

I, Jonathan C. Fox, M.D., Ph.D., hereby acknowledge and certify that I entered into a Transitional Service Agreement (the “Transitional Service Agreement”) with MyoKardia, Inc. Pursuant to the Transition Service Agreement and the Release Agreement, I am required to affirm the general release of claims in Transitional Service Agreement with respect to the period between the date I signed the Transitional Service Agreement and the Separation Date as that term is defined in the Transitional Service Agreement (the “Follow on Release”) as a Condition. I understand that I must sign this Follow on Release within ten (10) days of the Separation Date and that I may not sign this Follow on Release prior to the Separation Date.

I, therefore, agree as follows:

1. I hereby affirm the Release of Your Claims set forth in Section 12 of the Release Agreement and extend it to any and all Claims that, as of the date I sign this Follow on Release I have, own or hold, or claim to have, own, or hold, or that at I had, owned, or held, or claimed to have had, owned, or held against any Releasee, subject to all exclusions and terms set forth in the Transitional Service Agreement and to all obligations set forth in the Transition Service Agreement. To clarify, by signing this Follow-On release I do not release the Company from any claims under either the Transition Service Agreement or the Consulting Agreement.

2. I have carefully read and fully understand all of the provisions of this Follow on Release, I knowingly and voluntarily agree to all of the terms set forth in this Follow on Release.

3. I agree that this Follow on Release is hereby incorporated by reference into the Transitional Service Agreement.


Jonathan C. Fox, M.D., Ph.D.


Date

EXHIBIT C TO TRANSITIONAL SERVICES AGREEMENT

CONSULTING AGREEMENT

THIS CONSULTING AGREEMENT (together with the attached Business Terms Exhibit and Section 2870 Exhibit, the “Agreement”), is made by and between MYOKARDIA, INC., a Delaware corporation with an office at 333 Allerton Avenue, South San Francisco, CA 94080 (“MyoKardia”), and Jonathan C. Fox, M.D., Ph.D. with an address at 2235 3rd Street W-106, San Francisco, CA 94107 (“Consultant”). MyoKardia desires to have the benefit of Consultant’s knowledge and experience, and Consultant desires to provide services to MyoKardia, all as provided in this Agreement. This Agreement shall become effective on the date immediately following the Separation Date as defined in the Transitional Services Agreement by and between MyoKardia and Consultant (the “Effective Date”); provided, however, that if the Separation Date occurs due to either Consultant’s voluntary resignation from employment with MyoKardia or MyoKardia’s termination of Consultant’s employment with Cause (as defined in the Transitional Services Agreement), this Agreement shall not become effective on the Effective Date and shall be null and void.

Services; Exclusivity. MyoKardia retains Consultant, and Consultant agrees to provide, consulting and advisory services to MyoKardia as MyoKardia may from time to time reasonably request and as specified in the attached Business Terms Exhibit (the “Consulting Services”). Any changes to the Consulting Services (and any related compensation adjustments) must be agreed to in writing between Consultant and MyoKardia prior to implementation of the changes. During the Consulting Period (as defined in Section 9), Consultant agrees not to perform services, whether as an employee or an independent contractor, for a company other than MyoKardia that develops therapies for hypertrophic cardiomyopathy or heritable dilated cardiomyopathy.

2.	Compensation. As full consideration for Consulting Services provided under this Agreement, MyoKardia agrees to pay Consultant and reimburse expenses as described in the Business Terms Exhibit.

Performance. Consultant agrees to provide the Consulting Services to MyoKardia, or to its designee, in accordance with all applicable laws and regulations and the highest professional standards. Consultant represents and warrants that Consultant has not been, and is not under consideration to be (a) debarred from providing services pursuant to Section 306 of the United States Federal Food Drug and Cosmetic Act, 21 U.S.C. § 335a; (b) excluded, debarred or suspended from, or otherwise ineligible to participate in, any federal or state health care program or federal procurement or non-procurement programs (as that term is defined in 42 U.S.C. § 1320a-7b(f)); (c) disqualified by any government or regulatory agencies from performing specific services, and is not subject to a pending disqualification proceeding; or (d) convicted of a criminal offense related to the provision of health care items or services, or under investigation or subject to any such action that is pending. Consultant will notify MyoKardia immediately if Consultant is subject to the foregoing, or if any action, suit, claim, investigation, or proceeding relating to the foregoing is pending, or to the best of Consultant’s knowledge, is threatened.

Compliance with Obligations to Third Parties. Consultant represents and warrants to MyoKardia that the terms of this Agreement and Consultant’s performance of Consulting Services do not and will not conflict with any of Consultant’s obligations to any third parties. Consultant agrees not to use any trade secrets or other confidential information of any other person, firm, corporation, institution or other third party in connection with any of the Consulting Services. If Consultant is an employee of another company or institution, Consultant represents and warrants that Consultant is permitted to enter into this Agreement pursuant to such company’s or institution’s policies concerning professional consulting and additional workload. Consultant agrees not to make any use of any funds, space, personnel, facilities, equipment or other resources of a third party in performing the Consulting Services, nor take any other action that would result in a third party asserting ownership of, or other rights in, any Work Product (defined in Section 5), unless agreed upon in writing in advance by MyoKardia.

Work Product. Consultant will promptly and fully disclose in confidence to MyoKardia all inventions, discoveries, improvements, ideas, concepts, designs, processes, formulations, products, computer programs, works of authorship, databases, mask works, trade secrets, know-how, information, data, documentation, reports, research, creations and other products arising from or made in the performance of (solely or jointly with others) the Consulting Services (whether or not patentable or subject to copyright or trade secret protection) (collectively, the “Work Product”). Consultant assigns and agrees to assign to MyoKardia all rights in the United States and throughout the world to Work Product to and only to the fullest extent allowed by California Labor Code Section 2870 (which is attached as the Section 2870 Exhibit). Without disclosing any third party confidential information, Consultant will also disclose anything Consultant believes is excluded by Section 2870 so that MyoKardia can make an independent assessment. Consultant will keep and maintain adequate and current written records of all Work Product, and such records will be available to and remain the sole property of MyoKardia at all times. For purposes of the copyright laws of the United States, Work Product will constitute “works made for hire,” except to the extent such Work Product cannot by law be “works made for hire.” Consultant represents and warrants that Consultant has and will have the right to transfer and assign to MyoKardia ownership of all Work Product. Consultant will execute all documents, and take any and all actions needed, all without further consideration, in order to confirm MyoKardia’s rights as outlined above. In the event that Consultant should fail or refuse to execute such documents within a reasonable time, Consultant appoints MyoKardia as attorney to execute and deliver any such documents on Consultant’s behalf.

Confidentiality. “Confidential Information” means (a) any scientific, technical, business or financial information in whatever form (written, oral or visual) that is furnished or made available to Consultant by or on behalf of MyoKardia, (b) all information contained in or comprised of MyoKardia Materials (defined in Section 7); and (c) all Work Product. Confidential Information is, and will remain, the sole property of MyoKardia. During and after the Consulting Period, Consultant agrees to (i) hold in confidence all Confidential Information, and not disclose Confidential Information without the prior written consent of MyoKardia; (ii) use Confidential Information solely in connection with the Consulting Services; (iii) treat Confidential Information with no

less than a reasonable degree of care; (iv) reproduce Confidential Information solely to the extent necessary to provide the Consulting Services, with all such reproductions being considered Confidential Information; and (v) notify MyoKardia of any unauthorized disclosure of Confidential Information promptly upon becoming aware of such disclosure. Consultant’s obligations of non-disclosure and non-use under this Agreement will not apply to any portion of Confidential Information that Consultant can demonstrate, by competent proof:

(a)

is generally known to the public at the time of disclosure or becomes generally known through no wrongful act on the part of Consultant;

(b)

is in Consultant’s possession at the time of disclosure other than as a result of Consultant’s breach of any legal obligation;

(c)

becomes known to Consultant on a non-confidential basis through disclosure by sources other than MyoKardia having the legal right to disclose such Confidential Information; or

(d)

is independently developed by Consultant without reference to or reliance upon Confidential Information.

If Consultant is required by a governmental authority or by order of a court of competent jurisdiction to disclose any Confidential Information, Consultant will give MyoKardia prompt written notice thereof and Consultant will take all reasonable and lawful actions to avoid or minimize the degree of such disclosure. Consultant will cooperate reasonably with MyoKardia in any efforts to seek a protective order.

MyoKardia Materials. All documents, data, records, materials, compounds, apparatus, equipment and other physical property furnished or made available by or on behalf of MyoKardia to Consultant in connection with this Agreement (“MyoKardia Materials”) are and will remain the sole property of MyoKardia. Consultant will use MyoKardia Materials only as necessary to perform the Consulting Services and will not transfer or make available to any third party the MyoKardia Materials without the express prior written consent of MyoKardia. Consultant will return to MyoKardia any and all MyoKardia Materials upon request.

Publication; Publicity. Consultant may not publish or refer to Work Product, in whole or in part, without the prior express written consent of MyoKardia. Consultant will not use the name, logo, trade name, service mark, or trademark, or any simulation, abbreviation, or adaptation of same, or the name of MyoKardia or any of its affiliates for publicity, promotion, or other uses without MyoKardia’s prior written consent.

Expiration/Termination. The term of this Agreement will commence on the Effective Date and expire at the earliest of March 31, 2017 or the date that Consultant or MyoKardia sooner terminates this Agreement pursuant to this Section 9 (the “Consulting Period”). MyoKardia may terminate this Agreement at any time for Cause upon written notice to Consultant. A termination of this Agreement by MyoKardia with Cause shall include a breach of this Agreement by Consultant, including, without limitation, a

material breach of Consultant’s exclusivity obligation in Section 1 or material failure to perform the Consulting Services as set forth in the Business Terms Exhibit to this Agreement and a material breach of any of Consultant’s continuing obligations under the Transitional Services Agreement or the Employee Confidentiality and Assignment Agreement signed by Consultant on August 29, 2013 (the “Confidentiality Agreement”), which is incorporated by reference in Section 10(c) below. Consultant may terminate this Agreement at any time with or without cause upon not less than thirty (30) days’ prior written notice to MyoKardia. Any expiration or termination of this Agreement shall be without prejudice to any obligation of either party that has accrued prior to the effective date of expiration or termination. Upon expiration or termination of this Agreement, neither Consultant nor MyoKardia will have any further obligations under this Agreement, except that (a) Consultant will terminate all Consulting Services in progress in an orderly manner as soon as practicable and in accordance with a schedule agreed to by MyoKardia, unless MyoKardia specifies in the notice of termination that Consulting Services in progress should be completed; (b) Consultant will deliver to MyoKardia all Work Product made through expiration or termination; (c) MyoKardia will pay Consultant any monies due and owing Consultant, up to the time of termination or expiration, for Consulting Services properly performed and all authorized expenses actually incurred; (d) Consultant will immediately return to MyoKardia all MyoKardia Materials and other Confidential Information and copies thereof provided to Consultant under this Agreement; and (e) the terms, conditions and obligations under Sections 4, 5, 6, 7, 8 and 10 will survive expiration or termination of this Agreement. In the interest of clarity, vesting will cease upon the termination of the Consulting Period, provided MyoKardia may only terminate the Consulting Period prior to March 31, 2017 for Cause, as defined above.

10.	Miscellaneous.

(a)

Independent Contractor. The parties understand and agree that Consultant is an independent contractor and not an agent or employee of MyoKardia. Consultant has no authority to obligate MyoKardia by contract or otherwise. Consultant will not be eligible for any employee benefits of MyoKardia and expressly waives any rights to any employee benefits. Consultant will bear sole responsibility for paying and reporting Consultant’s own applicable federal and state income taxes, social security taxes, unemployment insurance, workers’ compensation, and health or disability insurance, retirement benefits, and other welfare or pension benefits, if any, and indemnifies and holds MyoKardia harmless from and against any liability with respect to such taxes, benefits and other matters.

(b)

Use of Name. Consultant consents to the use by MyoKardia of Consultant’s name on its website, in press releases, company brochures, offering documents, presentations, reports or other documents in printed or electronic form, and any documents filed with or submitted to any governmental or regulatory agency or any securities exchange or listing entity; provided, that such materials or presentations accurately describe the nature of Consultant’s relationship with or contribution to MyoKardia.

(c)

Entire Agreement. This Agreement, together with the Transitional Services Agreement, the Confidentiality Agreement, and the Equity Documents, contains the entire agreement of the parties with regard to its subject matter, and supersedes all prior or contemporaneous written or oral representations, agreements and understandings between the parties relating to that subject matter. This Agreement may be changed only by a writing signed by Consultant and an authorized representative of MyoKardia.

(d)

Certain Disclosures and Transparency. Consultant acknowledges that MyoKardia and its affiliates are required to abide by federal and state disclosure laws and certain transparency policies governing their activities including providing reports to the government and to the public concerning financial or other relationships with healthcare providers. Consultant agrees that MyoKardia and its affiliates may, in their sole discretion, disclose information about this Agreement and about Consultant’s Consulting Services including those relating to healthcare providers and any compensation paid to healthcare providers pursuant to this Agreement. Consultant agrees to promptly supply information reasonably requested by MyoKardia for disclosure purposes. To the extent that Consultant is independently obligated to disclose specific information concerning the Consulting Services relating to healthcare providers and compensation paid to healthcare providers pursuant to this Agreement, Consultant will make timely and accurate required disclosures.

(e)

Assignment and Binding Effect. The Consulting Services to be provided by Consultant are personal in nature. Consultant may not assign or transfer this Agreement or any of Consultant’s rights or obligations hereunder. In no event will Consultant assign or delegate responsibility for actual performance of the Consulting Services to any third party. MyoKardia may transfer or assign this Agreement, in whole or in part, without the prior written consent of Consultant. Any purported assignment or transfer in violation of this Section is void. This Agreement will be binding upon and inure to the benefit of the parties and their respective legal representatives, heirs, successors and permitted assigns.

(f)

Notices. All notices required or permitted under this Agreement must be in writing and must be given by directing the notice to the address for the receiving party set forth in this Agreement or at such other address as the receiving party may specify in writing under this procedure. Notices to MyoKardia will be marked “Attention: Legal Department”. All notices must be given (i) by personal delivery, with receipt acknowledged, (ii) by prepaid certified or registered mail, return receipt requested, or (iii) by prepaid recognized next business day delivery service. Notices will be effective upon receipt or at a later date stated in the notice.

(g)

Governing Law. This Agreement and any disputes relating to or arising out of this Agreement will be governed by, construed, and interpreted in accordance with the internal laws of the State of California, without regard to any choice of law principle that would require the application of the law of another jurisdiction.

The parties agree to submit to the exclusive jurisdiction of the state and federal courts located in the State of California and waive any defense of inconvenient forum to the maintenance of any action or proceeding in such courts.

(h)

Severability; Reformation. Each provision in this Agreement is independent and severable from the others, and no provision will be rendered unenforceable because any other provision is found by a proper authority to be invalid or unenforceable in whole or in part. If any provision of this Agreement is found by such an authority to be invalid or unenforceable in whole or in part, such provision shall be changed and interpreted so as to best accomplish the objectives of such unenforceable or invalid provision and the intent of the parties, within the limits of applicable law.

(i)

No Strict Construction; Headings. This Agreement has been prepared jointly and will not be strictly construed against either party. The section headings are included solely for convenience of reference and will not control or affect the meaning or interpretation of any of the provisions of this Agreement.

(j)

Waivers. Any delay in enforcing a party’s rights under this Agreement, or any waiver as to a particular default or other matter, will not constitute a waiver of such party’s rights to the future enforcement of its rights under this Agreement, except with respect to an express written waiver relating to a particular matter for a particular period of time signed by Consultant and an authorized representative of the waiving party, as applicable.

(k)

Remedies. Consultant agrees that (i) MyoKardia may be irreparably injured by a breach of this Agreement by Consultant; (ii) money damages would not be an adequate remedy for any such breach; (iii) as a remedy for any such breach MyoKardia will be entitled to seek equitable relief, including injunctive relief and specific performance, without being required by Consultant to post a bond; and (iv) such remedy will not be the exclusive remedy for any breach of this Agreement.

(l)

Counterparts. This Agreement may be executed in any number of counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. A facsimile or portable document format (“.pdf”) copy of this Agreement, including the signature pages, will be deemed an original.

[Signature page follows]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.

MYOKARDIA, INC.

JONATHAN C. FOX, M.D., PH.D.

By:				By:
Name:				Name:
Title:				Title:

[Signature Page to Jonathan C. Fox, M.D., Ph.D. Consulting Agreement]

BUSINESS TERMS EXHIBIT TO CONSULTING AGREEMENT

Consulting Agreement with Jonathan C. Fox, M.D., Ph.D.

1.	Consulting Services:

Consultant’s Consulting Services to MyoKardia will be on an as needed basis as determined by the Company’s CEO, provided in no event shall Consultant be required to perform Consulting Services more than 24 hours per week. The Consulting Services and are expected to include the following:

support of ongoing and future clinical trials for the HCM-1 and DCM-1 programs;

preparation, review, and consultation of materials in support of interactions with health authorities;

support for interactions with clinical investigators;

continued transitional services to support the clinical team; and

other services, as needed, customary of a chief medical advisor

Consultant will provide Consulting Services on a schedule and at a location or locations indicated above or as otherwise mutually agreed between Consultant and MyoKardia’s Chief Executive Officer. In addition, Consultant will be available for a reasonable number of telephone and/or written consultations.

2.	Compensation:

Fees: MyoKardia will pay Consultant $450.00 per hour not to exceed $200,000 during the Consulting Period, without MyoKardia’s express written consent.

Equity Vesting: During the Consulting Period (as defined in the Consulting Agreement), Consultant will continue to vest in the stock option grant made to Consultant by MyoKardia on March 13, 2013 consistent with the terms and conditions of consistent with the terms and conditions of Section 3 of the employment offer letter dated March 4, 2013 (the “Offer Letter”), the Stock Option Grant Notice dated March 13, 2013 (the “Stock Agreement”), and MyoKardia’s 2012 Equity Incentive Plan (the “Plan” and, together with Section 3 of the Offer Letter and the Stock Agreement, the “Equity Documents”). With respect to continued equity vesting, the terms of the Transitional Services Agreement and the Consulting Agreement will govern in the event of a contrary provision in the Offer Letter, the Stock Agreement, the Plan or the Equity Documents.

Expenses: MyoKardia will reimburse Consultant for any pre-approved expenses actually incurred by Consultant in connection with the provision of Consulting Services. Requests for reimbursement will be in a form reasonably acceptable to MyoKardia, will include supporting documentation and will accompany Consultant’s invoices.

Invoicing: No later than the last day of each calendar month, Consultant will invoice MyoKardia for Consulting Services rendered and related expenses incurred during the preceding month. Invoices should reference this Agreement and should be submitted to MyoKardia to the attention of: accounting@myokardia.com. Invoices will contain such detail as MyoKardia may reasonably require and will be payable in U.S. Dollars. Undisputed payments will be made by MyoKardia within thirty (30) days after MyoKardia’s receipt of Consultant’s invoice, request for reimbursement and all supporting documentation.

SECTION 2870 EXHIBIT

Consulting Agreement with Jonathan C. Fox, M.D., Ph.D.

California Labor Code Section 2870. Application of provision providing that employee shall assign or offer to assign rights in invention to employer.

(a) Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either:

(1) Relate at the time of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the employer; or

(2) Result from any work performed by the employee for his employer.

(b) To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.

EX-31.1 3 myok-ex311_6.htm EX-31.1 myok-ex311_6.htm

Exhibit 31.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO

SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)

I, Tassos Gianakakos, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of MyoKardia, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(c)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 12, 2016

/s/ Tassos Gianakakos

Tassos Gianakakos

President, Chief Executive Officer

(principal executive officer)

EX-31.2 4 myok-ex312_9.htm EX-31.2 myok-ex312_9.htm

Exhibit 31.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)

I, Steven Chan, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of MyoKardia, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)

(b)

(c)

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 12, 2016

/s/ Steven Chan

Steven Chan

Vice President, Corporate Controller

(principal financial and accounting officer)

EX-32.1 5 myok-ex321_7.htm EX-32.1 myok-ex321_7.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of MyoKardia, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended March 31, 2016, as filed with the Securities and Exchange Commission (the “Report”), Tassos Gianakakos, President, Chief Executive Officer of the Company, and Steven Chan, Vice President and Corporate Controller of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 12, 2016

/s/ Tassos Gianakakos
Tassos Gianakakos
President, Chief Executive Officer (principal executive officer)

/s/ Steven Chan
Steven Chan Vice President, Corporate Controller (principal financial and accounting officer)

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of MyoKardia, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-101.INS 6 myok-20160331.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares myok:Program utr:sqft 0001552451 2016-01-01 2016-03-31 0001552451 2016-05-05 0001552451 2016-03-31 0001552451 2015-12-31 0001552451 2015-01-01 2015-03-31 0001552451 2014-12-31 0001552451 2015-03-31 0001552451 myok:SeriesAA1AndSeriesBRedeemableConvertiblePreferredStockMember 2015-03-01 2015-03-31 0001552451 us-gaap:IPOMember 2015-11-02 2015-11-03 0001552451 us-gaap:IPOMember 2015-11-03 0001552451 2015-11-02 2015-11-03 0001552451 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0001552451 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0001552451 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001552451 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001552451 us-gaap:MandatorilyRedeemablePreferredStockMember 2014-12-31 0001552451 us-gaap:MandatorilyRedeemablePreferredStockMember 2015-01-01 2015-03-31 0001552451 myok:AventisIncMember us-gaap:CollaborativeArrangementMember us-gaap:MaximumMember 2014-08-01 2014-08-31 0001552451 myok:AventisIncMember us-gaap:CollaborativeArrangementMember 2014-08-01 2014-08-31 0001552451 us-gaap:CollaborativeArrangementMember myok:AventisIncMember 2014-08-31 0001552451 us-gaap:CollaborativeArrangementMember myok:AventisIncMember 2016-03-31 0001552451 us-gaap:CollaborativeArrangementMember myok:AventisIncMember 2015-12-31 0001552451 us-gaap:CollaborativeArrangementMember myok:AventisIncMember 2016-01-01 2016-03-31 0001552451 us-gaap:CollaborativeArrangementMember myok:AventisIncMember 2015-01-01 2015-03-31 0001552451 us-gaap:CollaborativeArrangementMember myok:AventisIncMember myok:SeriesAOneRedeemableConvertiblePreferredStockMember 2014-08-01 2014-08-31 0001552451 us-gaap:CollaborativeArrangementMember myok:AventisIncMember myok:SeriesAOneRedeemableConvertiblePreferredStockMember 2014-08-31 0001552451 myok:AventisIncMember us-gaap:CollaborativeArrangementMember myok:SeriesBRedeemableConvertiblePreferredStockMember 2015-04-01 2015-04-30 0001552451 us-gaap:CollaborativeArrangementMember myok:AventisIncMember 2015-01-01 2015-12-31 0001552451 us-gaap:CollaborativeArrangementMember myok:AventisIncMember 2014-01-01 2014-12-31 0001552451 us-gaap:MachineryAndEquipmentMember 2016-03-31 0001552451 us-gaap:MachineryAndEquipmentMember 2015-12-31 0001552451 us-gaap:FurnitureAndFixturesMember 2016-03-31 0001552451 us-gaap:FurnitureAndFixturesMember 2015-12-31 0001552451 us-gaap:SoftwareDevelopmentMember 2016-03-31 0001552451 us-gaap:SoftwareDevelopmentMember 2015-12-31 0001552451 us-gaap:LeaseholdImprovementsMember 2016-03-31 0001552451 us-gaap:LeaseholdImprovementsMember 2015-12-31 0001552451 myok:FacilityLeasesMember 2012-06-28 2012-06-29 0001552451 myok:FacilityLeasesMember 2012-06-29 0001552451 myok:FacilityLeasesMember 2016-01-01 2016-03-31 0001552451 myok:FacilityLeasesMember 2014-09-14 2014-09-15 0001552451 myok:FacilityLeasesMember 2014-09-15 0001552451 us-gaap:EmployeeStockOptionMember 2016-03-31 0001552451 us-gaap:EmployeeStockOptionMember 2015-12-31 0001552451 myok:TwoThousandFifteenStockOptionAndIncentivePlanMember 2016-03-31 0001552451 myok:TwoThousandFifteenStockOptionAndIncentivePlanMember 2015-12-31 0001552451 myok:TwoThousandFifteenEmployeeStockPurchasePlanMember 2016-03-31 0001552451 myok:TwoThousandFifteenEmployeeStockPurchasePlanMember 2015-12-31 0001552451 us-gaap:RedeemableConvertiblePreferredStockMember 2015-10-31 0001552451 myok:SeriesARedeemableConvertiblePreferredStockMember 2015-10-31 0001552451 myok:SeriesAOneRedeemableConvertiblePreferredStockMember 2015-10-31 0001552451 myok:SeriesBRedeemableConvertiblePreferredStockMember 2015-10-31 0001552451 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-03-31 0001552451 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-03-31 0001552451 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0001552451 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-03-31 0001552451 myok:CommonStockSubjectToRepurchaseMember 2016-01-01 2016-03-31 0001552451 myok:CommonStockSubjectToRepurchaseMember 2015-01-01 2015-03-31 0001552451 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0001552451 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-03-31 0001552451 us-gaap:MajorityShareholderMember 2016-01-01 2016-03-31 0001552451 us-gaap:MajorityShareholderMember 2015-01-01 2015-03-31 0001552451 us-gaap:MajorityShareholderMember 2016-03-31 0001552451 us-gaap:MajorityShareholderMember 2015-12-31 0001552451 myok:GlobalBloodTherapeuticsMember 2016-01-01 2016-03-31 0001552451 myok:GlobalBloodTherapeuticsMember 2015-01-01 2015-03-31 0001552451 myok:GlobalBloodTherapeuticsMember 2016-03-31 0001552451 myok:GlobalBloodTherapeuticsMember 2015-12-31 10-Q false 2016-03-31 2016 Q1 MYOK MyoKardia Inc 0001552451 --12-31 Non-accelerated Filer 27041110

99495000

112265000

1245000

1282000

100740000

113547000

3007000

2744000

289000

104036000

116580000

1994000

2143000

4827000

5633000

10649000

14199000

17470000

21975000

658000

732000

18128000

22707000

3000

159010000

158555000

-73105000

-64685000

85908000

93873000

104036000

116580000

0.0001

5000000

0.0001

150000000

27016082

27053156

27016082

27053156

3550000 3550000

8130000

6616000

3860000

1765000

11990000

8381000

-8440000

-4831000

20000 17000 314000

-8420000

-4500000

952000

33000

-8420000

-5485000

-0.32

-2.47

26169152

2221751

256000

254000

414000

35000

15000

-37000

313000

-115000

323000

-666000

71000

-11000

307000

-3550000

-12055000

-7702000

562000

134000

-562000

-428000

99000

153000

-153000

99000

-12770000

-8031000

43648000

35617000

71000 29000

13000

48000

5000 229000

<div> 3. Fair Value Measurements Financial assets and liabilities are recorded at fair value. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows: Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2—Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. The following table sets forth a summary of the changes in the fair value of the Company’s Level 1 financial instruments as follows (in thousands):    <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at March 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money Market funds</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,060</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,060</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money Market funds</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,533</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,533</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.84%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.22%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">call option liability, net</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2014</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value recorded in statement of operations and comprehensive loss</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(314</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2015</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>    </div>

<div> 5. Balance Sheet Components Property and Equipment Property and equipment consist of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Scientific equipment</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,462</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,995</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">352</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized software</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">225</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">225</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">304</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">303</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,343</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,824</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation and amortization</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,336</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,080</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,007</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,744</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Depreciation and amortization expense was $0.3 million and $0.3 million for the three months ended March 31, 2016 and 2015, respectively. Accrued Liabilities Accrued liabilities consist of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and related expenses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,522</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,515</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical research and development</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,478</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,145</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal and accounting fees</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">371</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">456</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">940</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,827</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,633</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> 8. Stock-Based Compensation The Company classifies stock-based compensation expense in the accompanying condensed consolidated statements of operations and comprehensive loss based on the department to which a recipient belongs. The following table sets forth stock-based compensation expense related to options granted to employees and consultants for all periods presented (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">414</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The following summarizes option activity under the 2012 Equity Incentive Plan and 2015 Stock Option and Incentive Plan:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.72%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Subject to</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.72%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding Options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price Per Share</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2015</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,647</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.29</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">605,134</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.80</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options canceled</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,600</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.00</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2016</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,910,181</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.30</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   In relation to stock options to purchase common stock that vest upon the achievement of performance criteria, no stock-based compensation expense had been recorded as of March 31, 2016, because the Company concluded that the achievement of the applicable performance criteria had not been considered probable.  </div>

<div> 9. Net Loss per Share Attributable to Common Stockholders The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,420</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,500</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative dividends on redeemable convertible preferred stock</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(952</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion of redeemable convertible preferred stock to redemption value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders, basic and diluted</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,420</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,485</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,024,638</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,752,389</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: weighted average shares subject to repurchase</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(855,486</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,530,638</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares used to compute basic and diluted net loss per share</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,169,152</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,221,751</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders: Basic and diluted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.32</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.47</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div>   The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">806,035</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,465,685</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options to purchase common stock</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,910,181</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">458,887</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s consolidated financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), the Company meets the definition of an emerging growth company, and has irrevocably elected to opt out of the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. In March 2016, the FASB issued Accounting Standard Update (“ASU”) No. 2016-10, Revenue from Contracts, which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU will provide a more robust framework for recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation. This framework will help to improve comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets and provide more useful information to users of financial statements through improved disclosure requirements. For a public entity, the amendments in ASU 2016-10 are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Company has not determined the potential effects of this standard on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Share-Based Compensation, with the objective to identify, evaluate, and improve areas of generally accepted accounting principles (GAAP) for which cost and complexity can be reduced while maintaining or improving the usefulness of the information provided to users of financial statements. The areas for simplification in ASU 2016-09 involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public business entities, the amendments in ASU 2016-09 are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for any entity in any interim or annual period. The Company is currently evaluating the impact of this standard on its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02 (Topic 842), Leases. ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has not determined the potential effects of this standard on its consolidated financial statements. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern. The new standard provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. ASU 2014-12 requires that a performance target that affects vesting and could be achieved after the requisite service period be treated as a performance condition. ASU 2014-12 is effective for the Company in its first quarter of 2016 with early adoption permitted. The Company has determined that the adoption of this standard did not have a material impact on its consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The ASU is effective for public entities for annual and interim periods beginning after December 15, 2017, with early adoption for fiscal 2017 permitted. The Company has not determined the potential effects of this standard on its consolidated financial statements.</div>

<div> The following table sets forth a summary of the changes in the fair value of the Company’s Level 1 financial instruments as follows (in thousands):    <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at March 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money Market funds</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,060</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,060</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money Market funds</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,533</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,533</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.84%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.22%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">call option liability, net</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2014</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value recorded in statement of operations and comprehensive loss</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(314</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2015</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Property and equipment consist of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Scientific equipment</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,462</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,995</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">352</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized software</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">225</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">225</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">304</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">303</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,343</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,824</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation and amortization</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,336</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,080</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,007</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,744</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Accrued liabilities consist of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and related expenses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,522</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,515</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical research and development</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,478</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,145</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal and accounting fees</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">371</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">456</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">940</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,827</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,633</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The Company has reserved shares of common stock for issuance as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued and outstanding</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,910,181</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,647</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for issuance under 2015 Stock Option and Incentive Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">942,611</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,497,071</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for issuance under 2015 Employee Stock Purchase Plan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,107,792</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,070,718</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following summarizes option activity under the 2012 Equity Incentive Plan and 2015 Stock Option and Incentive Plan:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.72%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Subject to</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.72%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding Options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price Per Share</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2015</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,647</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.29</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">605,134</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.80</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options canceled</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,600</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.00</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2016</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,910,181</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.30</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,420</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,500</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative dividends on redeemable convertible preferred stock</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(952</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion of redeemable convertible preferred stock to redemption value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders, basic and diluted</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,420</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,485</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,024,638</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,752,389</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: weighted average shares subject to repurchase</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(855,486</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,530,638</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares used to compute basic and diluted net loss per share</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,169,152</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,221,751</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders: Basic and diluted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.32</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.47</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div>  </div>

<div> The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">806,035</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,465,685</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options to purchase common stock</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,910,181</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">458,887</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

93900000

6253125

10.00

55600000

99060000

111533000

314000

-314000 200000000 35000000 10000000 25000000 85000000 45000000 P4Y 3

35000000

10600000

14200000

3600000

6666667

1.50

45000000 40000000 an additional $40.0 million in connection with the purchase of the Company’s preferred stock, assuming (i) the Company had not previously closed either a Qualified IPO (at which time this obligation would terminate) or a private financing prior to a Qualified IPO and (ii) Sanofi had not previously purchased shares of the Company’s stock pursuant to such rights to purchase the Company’s capital stock in accordance with the terms of the Collaboration Agreement. 5000000 35000000

40000000

700000

-300000

-400000

4462000

3995000

352000

301000

225000

304000

303000

5343000

4824000

2336000

2080000

1522000

2515000

2478000 2145000

371000

33000

456000

940000

P30D

P66M

12000

500000

100000

P5Y

34400

P3Y

1300000

1600000

2015-01 P3M

300000

1910181

1318647

942611

1497071

255000

3107792

3070718

62235313

0.0001

38500000

6666667

17068646

174000

18000

240000

17000

414000

35000

1318647

605134

13600

1910181

2.29

8.80

10.00

4.30

27024638

3752389

855486

1530638

806035

1465685

1910181

458887

22000

31000

23000

13000

0 33000

EX-101.SCH 7 myok-20160331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100050 - Disclosure - Formation and Business of the Company link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Collaboration and License Agreement link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Balance Sheet Components link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Net Loss per Share Attributable to Common Stockholders link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Balance Sheet Components (Tables) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Formation and Business of the Company - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Details) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Company's Level 3 Financial Instruments (Details) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Collaboration and License Agreement - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Balance Sheet Components - Summary of Property and Equipment (Details) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Balance Sheet Components - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Stockholders' Equity- Schedule of Common Stock Reserved for Issuance(Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Stockholders' Equity - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Options Granted to Employees and Consultants (Details) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity Under Plans (Details) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Details) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Related Party Transactions - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 myok-20160331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 myok-20160331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 myok-20160331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document and entity information. Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Other long term assets Other Assets Noncurrent Total assets Assets Liabilities and stockholders’ equity Liabilities And Stockholders Equity [Abstract] Current liabilities Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued liabilities Accrued Liabilities Current Deferred revenue Deferred Revenue Current Total current liabilities Liabilities Current Other long-term liabilities Other Liabilities Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 6) Commitments And Contingencies Stockholders’ equity (deficit) Stockholders Equity [Abstract] Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding Preferred Stock Value Common stock, $0.0001 par value, 150,000,000 shares authorized at March 31, 2016 and December 31, 2015; 27,016,082 and 27,053,156 shares, issued and outstanding at March 31, 2016 and December 31, 2015, respectively Common Stock Value Additional paid-in-capital Additional Paid In Capital Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Collaboration and license revenue. Interest and other income (expense), net. Change in fair value of temporary equity call option liability. Income Statement [Abstract] Collaboration and license revenue Collaboration And License Revenue Operating expenses Operating Expenses [Abstract] Research and development Research And Development Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Interest and other income, net Interest And Other Income Expense Net Change in fair value of redeemable convertible preferred stock call option liability Change In Fair Value Of Temporary Equity Call Option Liability Net loss and comprehensive loss Net Income Loss Cumulative dividend relating to redeemable convertible preferred stock Temporary Equity Dividends Adjustment Accretion of redeemable convertible preferred stock to redemption value Temporary Equity Accretion To Redemption Value Adjustment Net loss attributable to common stockholders Net Income Loss Available To Common Stockholders Basic Net loss per share attributable to common stockholders, basic and diluted Earnings Per Share Basic And Diluted Weighted-average number of common shares used to compute net loss per share, basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Vesting of early exercised options and restricted stock. Unpaid portion of property and equipment purchases included in accrued liabilities. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Net loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation And Amortization Stock-based compensation expense Share Based Compensation Gain on sale of equipment Gain Loss On Sale Of Property Plant Equipment Change in fair value of redeemable convertible preferred stock call option liability, net Change in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Prepaid expenses and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable Accrued liabilities Increase Decrease In Accrued Liabilities Other long term liabilities Increase Decrease In Other Noncurrent Liabilities Deferred revenue Increase Decrease In Deferred Revenue Net cash used in operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Cash flows from investing activities: Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Purchases of property and equipment Payments To Acquire Property Plant And Equipment Proceeds from sale of equipment Proceeds From Sale Of Machinery And Equipment Net cash used in investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Cash flows from financing activities: Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Proceeds from issuance of common stock Proceeds From Issuance Of Common Stock Payments of deferred offering costs Payments Of Stock Issuance Costs Net cash (used in) provided by financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Net decrease in cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Supplemental disclosures of noncash investing and financing information Noncash Investing And Financing Items [Abstract] Vesting of early exercised options and restricted stock Vesting Of Early Exercised Options And Restricted Stock Unpaid portion of property and equipment purchases included in period-end accounts payable Capital Expenditures Incurred But Not Yet Paid Unpaid portion of property and equipment purchases included in period-end accrued liabilities Unpaid Portion Of Property And Equipment Purchases Included In Accrued Liabilities Accretion of dividends on redeemable convertible preferred stock Accretion of redeemable convertible preferred stock to redemption value Organization Consolidation And Presentation Of Financial Statements [Abstract] Formation and Business of the Company Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Collaboration and license agreement disclosure. Collaboration And License Agreement Disclosure [Abstract] Collaboration and License Agreement Collaborative Arrangement Disclosure [Text Block] Balance Sheet Related Disclosures [Abstract] Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Stockholders Equity Note [Abstract] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Earnings Per Share [Abstract] Net Loss per Share Attributable to Common Stockholders Earnings Per Share [Text Block] Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Summary of Changes in Fair Value of Financial Instruments Fair Value Assets Measured On Recurring Basis [Text Block] Summary of Changes in Fair Value of Company's Level 3 Financial Instruments Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block] Summary of Property and Equipment Property Plant And Equipment [Text Block] Summary of Accrued Liabilities Schedule Of Accrued Liabilities Table [Text Block] Schedule of common stock reserved for issuance. Equity [Abstract] Schedule of Common Stock Reserved for Issuance Schedule Of Common Stock Reserved For Issuance Table [Text Block] Schedule of Stock-Based Compensation Expense Related to Options Granted to Employees and Consultants Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Summary of Stock Option Activity Under Plans Schedule Of Share Based Compensation Activity Table [Text Block] Computation of Basic and Diluted Net Loss per Share Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Organization, consolidation and presentation of financial statements. Organization consolidation and presentation of financial statements. Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] IPO I P O [Member] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Series A, A-1 and series B redeemable convertible preferred stock. Series A, A-1 and Series B Redeemable Convertible Preferred Stock Series A A1 And Series B Redeemable Convertible Preferred Stock [Member] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Net proceeds from sale of shares of convertible stock Proceeds From Issuance Of Convertible Preferred Stock Issuance of common stock Stock Issued During Period Shares New Issues Shares issued, price per share Sale Of Stock Price Per Share Net proceeds from initial public offering Proceeds From Issuance Initial Public Offering Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Measurement Frequency Fair Value By Measurement Frequency [Axis] Fair Value, Measurement Frequency Fair Value Measurement Frequency [Domain] Fair Value Measurements on Recurring Basis Fair Value Measurements Recurring [Member] Fair Value, Hierarchy Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy Fair Value Measurements Fair Value Hierarchy [Domain] Level 1 Fair Value Inputs Level1 [Member] Level 2 Fair Value Inputs Level2 [Member] Level 3 Fair Value Inputs Level3 [Member] Asset Class Fair Value By Asset Class [Axis] Asset Class Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Money market funds Money Market Funds [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Assets Assets Fair Value Disclosure [Abstract] Assets fair value Assets Fair Value Disclosure Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings and other comprehensive income (loss). Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Liability Class Fair Value By Liability Class [Axis] Fair Value by Liability Class Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain] Convertible Preferred Stock Call Option Liability, Net Mandatorily Redeemable Preferred Stock [Member] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Beginning balance Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Change in fair value recorded in statement of operations and comprehensive loss Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings And Other Comprehensive Income Loss Ending balance Collaboration agreement consideration amount. Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Aventis Inc. Sanofi (Aventis Inc.) Aventis Inc [Member] Type of Arrangement and Non-arrangement Transactions Type Of Arrangement [Axis] Arrangements and Non-arrangement Transactions Arrangements And Nonarrangement Transactions [Member] Collaborative Agreement Collaborative Arrangement [Member] Range Range [Axis] Range Range [Member] Maximum Maximum [Member] Series A-1 redeemable convertible preferred stock. Series A-1 Redeemable Convertible Preferred Stock Series A One Redeemable Convertible Preferred Stock [Member] Series B redeemable convertible preferred stock. Series B Redeemable Convertible Preferred Stock Series B Redeemable Convertible Preferred Stock [Member] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Proceeds from collaboration agreement Collaboration Agreement Consideration Amount Proceeds from upfront cash payment. Upfront cash received under collaboration agreement Proceeds From Upfront Cash Payment Proceeds from initial equity investment. Initial equity investment Proceeds From Initial Equity Investment Eligible milestone payments receivable. Eligible to receive milestone payment Eligible Milestone Payments Receivable Eligible project continuation cash payment upon achievement. Project continuation payment Eligible Project Continuation Cash Payment Upon Achievement Funding from approved in-kind research and clinical activities. In-kind research and clinical activity funding period. Funding from approved in-kind research and clinical activities Funding From Approved In Kind Research And Clinical Activities Period for research and clinical activities In Kind Research And Clinical Activity Funding Period Number of research programs. Number of research programs Number Of Research Programs Deferred revenue Deferred Revenue Revenue recognized under collaboration agreement Deferred Revenue Revenue Recognized Fair value of stock per share price Shares Issued Price Per Share One time non-refundable non-creditable cash payment. One-time non-refundable non-creditable cash payment One Time Non Refundable Non Creditable Cash Payment Eligible project continuation additional payment. Eligible project continuation additional payment description. Decrease in eligible project continuation additional payment. Project continuation, additional payment Eligible Project Continuation Additional Payment Project continuation, additional payment description Eligible Project Continuation Additional Payment Description Decrease in project continuation additional payment Decrease In Eligible Project Continuation Additional Payment Time restricted rights to purchase stock, value Stock Issued During Period Value Purchase Of Assets Convertible preferred stock at discount Preferred Stock Including Additional Paid In Capital Net Of Discount Redeemable convertible preferred stock call option liability fair value. Redeemable convertible preferred stock call option liability fair value Redeemable Convertible Preferred Stock Call Option Liability Fair Value Change in fair value of redeemable convertible preferred stock call option liability Fair Value Option Changes In Fair Value Gain Loss1 Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment, Type Property Plant And Equipment By Type [Axis] Property, Plant and Equipment, Type Property Plant And Equipment Type [Domain] Scientific Equipment Machinery And Equipment [Member] Furniture and Equipment Furniture And Fixtures [Member] Capitalized Software Software Development [Member] Leasehold Improvements Leasehold Improvements [Member] Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] EX-101.PRE 11 myok-20160331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2016	May. 05, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1
Trading Symbol	MYOK
Entity Registrant Name	MyoKardia Inc
Entity Central Index Key	0001552451
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		27,041,110

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 99,495	$ 112,265
Prepaid expenses and other current assets	1,245	1,282
Total current assets	100,740	113,547
Property and equipment, net	3,007	2,744
Other long term assets	289	289
Total assets	104,036	116,580
Current liabilities
Accounts payable	1,994	2,143
Accrued liabilities	4,827	5,633
Deferred revenue	10,649	14,199
Total current liabilities	17,470	21,975
Other long-term liabilities	658	732
Total liabilities	$ 18,128	$ 22,707
Commitments and contingencies (Note 6)
Stockholders’ equity (deficit)
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding
Common stock, $0.0001 par value, 150,000,000 shares authorized at March 31, 2016 and December 31, 2015; 27,016,082 and 27,053,156 shares, issued and outstanding at March 31, 2016 and December 31, 2015, respectively	$ 3	$ 3
Additional paid-in-capital	159,010	158,555
Accumulated deficit	(73,105)	(64,685)
Total stockholders’ equity	85,908	93,873
Total liabilities and stockholders’ equity	$ 104,036	$ 116,580

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	27,016,082	27,053,156
Common stock, shares outstanding	27,016,082	27,053,156

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Collaboration and license revenue	$ 3,550	$ 3,550
Operating expenses
Research and development	8,130	6,616
General and administrative	3,860	1,765
Total operating expenses	11,990	8,381
Loss from operations	(8,440)	(4,831)
Interest and other income, net	20	17
Change in fair value of redeemable convertible preferred stock call option liability		314
Net loss and comprehensive loss	(8,420)	(4,500)
Cumulative dividend relating to redeemable convertible preferred stock		(952)
Accretion of redeemable convertible preferred stock to redemption value		(33)
Net loss attributable to common stockholders	$ (8,420)	$ (5,485)
Net loss per share attributable to common stockholders, basic and diluted	$ (0.32)	$ (2.47)
Weighted-average number of common shares used to compute net loss per share, basic and diluted	26,169,152	2,221,751

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net loss	$ (8,420)	$ (4,500)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	256	254
Stock-based compensation expense	414	35
Gain on sale of equipment		(15)
Change in fair value of redeemable convertible preferred stock call option liability, net		(314)
Change in operating assets and liabilities:
Prepaid expenses and other assets	37	(313)
Accounts payable	(115)	323
Accrued liabilities	(666)	71
Other long term liabilities	(11)	307
Deferred revenue	(3,550)	(3,550)
Net cash used in operating activities	(12,055)	(7,702)
Cash flows from investing activities:
Purchases of property and equipment	(562)	(562)
Proceeds from sale of equipment		134
Net cash used in investing activities	(562)	(428)
Cash flows from financing activities:
Proceeds from issuance of common stock		99
Payments of deferred offering costs	(153)
Net cash (used in) provided by financing activities	(153)	99
Net decrease in cash and cash equivalents	(12,770)	(8,031)
Cash and cash equivalents, beginning of period	112,265	43,648
Cash and cash equivalents, end of period	99,495	35,617
Supplemental disclosures of noncash investing and financing information
Vesting of early exercised options and restricted stock	71	29
Unpaid portion of property and equipment purchases included in period-end accounts payable	13	48
Unpaid portion of property and equipment purchases included in period-end accrued liabilities	$ 5	229
Accretion of dividends on redeemable convertible preferred stock		952
Accretion of redeemable convertible preferred stock to redemption value		$ 33

XML 17 R6.htm IDEA: XBRL DOCUMENT

Formation and Business of the Company	3 Months Ended
Formation and Business of the Company	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Formation and Business of the Company	1. Formation and Business of the Company MyoKardia, Inc., incorporated under the laws of the State of Delaware in June 2012, is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. We have used our precision medicine platform to generate an initial pipeline of four therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy—hypertrophic cardiomyopathy (“HCM”), and dilated cardiomyopathy (“DCM”). We have discovered and advanced our lead product candidate, MYK-461, into Phase 1 clinical development. In our first Phase 1 clinical trial, we have demonstrated proof of mechanism, or the ability of MYK-461 to reduce cardiac muscle contraction, an important biomarker of disease. We intend to expand our approach to deliver treatments with disease-modifying potential for patients with other forms of genetically-driven heart failure. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Through March 31, 2016, the Company has financed its operations through an initial public offering (“IPO”) and private placements of redeemable convertible preferred stock and funds received in connection with a license and collaboration agreement with Aventis Inc., a wholly-owned subsidiary of Sanofi S.A., entered into in August 2014 (the “Collaboration Agreement”) (See Note 4). The Company received net proceeds of $93.9 million from the sale of shares of its Series A, A-1 and B redeemable convertible preferred stock. On November 3, 2015, the Company completed its IPO of 6,253,125 shares of common stock at an offering price of $10.00 per share, resulting in net proceeds of approximately $55.6 million, after deducting underwriting discounts, commissions and offering costs. The Company has incurred significant losses and negative cash flows from operations. As at March 31, 2016, the Company had an accumulated deficit of $73.1 million and cash and cash equivalents of $99.5 million, which it believes will be sufficient to fund its planned operations through at least the next twelve months. The accompanying unaudited Condensed Consolidated Financial Statements, in the opinion of management, include all adjustments which the Company considers necessary for the fair statement of the Condensed Consolidated Results of Operations and Comprehensive Loss and Cash Flows for the interim periods covered and the Condensed Consolidated Financial Position of the Company at the date of the balance sheets. The consolidated financial statements of the Company as at December 31, 2015 included the Company’s accounts and have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2016, or any other future period. The accompanying unaudited Condensed Consolidated Financial Statements and related financial information should be read in conjunction with the Company’s audited consolidated financial statements and the related notes thereto for the year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 18, 2016 (the “Annual Report”).

XML 18 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies	3 Months Ended
Summary of Significant Accounting Policies	Mar. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Significant accounting policies are described in Note 2 to the consolidated financial statements for the year ended December 31, 2015 included in the Annual Report. There have been no changes to the Company’s significant accounting policies during the three months ended March 31, 2016. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s consolidated financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), the Company meets the definition of an emerging growth company, and has irrevocably elected to opt out of the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. In March 2016, the FASB issued Accounting Standard Update (“ASU”) No. 2016-10, Revenue from Contracts, which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU will provide a more robust framework for recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation. This framework will help to improve comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets and provide more useful information to users of financial statements through improved disclosure requirements. For a public entity, the amendments in ASU 2016-10 are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Company has not determined the potential effects of this standard on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Share-Based Compensation, with the objective to identify, evaluate, and improve areas of generally accepted accounting principles (GAAP) for which cost and complexity can be reduced while maintaining or improving the usefulness of the information provided to users of financial statements. The areas for simplification in ASU 2016-09 involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public business entities, the amendments in ASU 2016-09 are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for any entity in any interim or annual period. The Company is currently evaluating the impact of this standard on its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02 (Topic 842), Leases. ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has not determined the potential effects of this standard on its consolidated financial statements. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern. The new standard provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. ASU 2014-12 requires that a performance target that affects vesting and could be achieved after the requisite service period be treated as a performance condition. ASU 2014-12 is effective for the Company in its first quarter of 2016 with early adoption permitted. The Company has determined that the adoption of this standard did not have a material impact on its consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The ASU is effective for public entities for annual and interim periods beginning after December 15, 2017, with early adoption for fiscal 2017 permitted. The Company has not determined the potential effects of this standard on its consolidated financial statements.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Mar. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurements

3. Fair Value Measurements

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

The following table sets forth a summary of the changes in the fair value of the Company’s Level 1 financial instruments as follows (in thousands):

	Fair Value Measurements at March 31, 2016
	Total		Level 1		Level 2		Level 3
Assets
Money Market funds	$	99,060	$	99,060	$	—	$	—

	Fair Value Measurements at December 31, 2015
	Total		Level 1		Level 2		Level 3
Assets
Money Market funds	$	111,533	$	111,533	$	—	$	—

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments as follows (in thousands):

	Convertible preferred stock
	call option liability, net
Balance at December 31, 2014	$	314
Change in fair value recorded in statement of operations and comprehensive loss		(314	)
Balance at March 31, 2015	$	—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 20 R9.htm IDEA: XBRL DOCUMENT

Collaboration and License Agreement

3 Months Ended

Mar. 31, 2016

Collaboration And License Agreement Disclosure [Abstract]

Collaboration and License Agreement

4. Collaboration and License Agreement

Sanofi (Aventis Inc.)

a $35.0 million upfront cash payment;

a $10.0 million initial equity investment;

a $25.0 million milestone-based contingent payment;

up to an $85.0 million project continuation payment if Sanofi elects to extend the term of the research collaboration beyond December 31, 2016, as described below; and

up to $45.0 million in funding from Sanofi of approved in-kind research and clinical activities over a four-year period.

The Company accounted for the Collaboration Agreement by evaluating each of the financial components discussed above:

a one-time, non-refundable, non-creditable cash payment of $45.0 million

As of March 31, 2016, Sanofi had not provided the confirmation of continuation under the Collaboration Agreement.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Balance Sheet Components

3 Months Ended

Mar. 31, 2016

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Components

5. Balance Sheet Components

Property and Equipment

Property and equipment consist of the following (in thousands):

	March 31, 2016			December 31, 2015
Scientific equipment	$	4,462		$	3,995
Furniture and equipment		352			301
Capitalized software		225			225
Leasehold improvements		304			303
Total		5,343			4,824
Less: Accumulated depreciation and amortization		(2,336	)		(2,080	)
Property and equipment, net	$	3,007		$	2,744

Depreciation and amortization expense was $0.3 million and $0.3 million for the three months ended March 31, 2016 and 2015, respectively.

Accrued Liabilities

Accrued liabilities consist of the following (in thousands):

	March 31, 2016		December 31, 2015
Payroll and related expenses	$	1,522	$	2,515
Clinical research and development		2,478		2,145
Legal and accounting fees		371		33
Other		456		940
Total accrued liabilities	$	4,827	$	5,633

XML 22 R11.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	6. Commitments and Contingencies Purchase Commitments The Company conducts product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. The Company has contractual arrangements with these organizations; however, these contracts are generally cancelable on 30 days’ notice and the obligations under these contracts are largely based on services performed. Facility Leases On June 29, 2012, the Company entered into a 66-month lease for approximately 12,000 square feet of office and laboratory space in South San Francisco with annual payments of approximately $0.5 million. In connection with this lease agreement, the Company also entered into a shared facilities and services agreement with Global Blood Therapeutics, Inc. (“GBT”), a co-tenant in the office building (See Note 10). In October 2014, the Company entered into a lease assignment agreement with the owner of the building and GBT to allow GBT to sublease the Company’s portion of the building beginning in March 2015. For the three months ended March 31, 2016, the Company recorded approximately $0.1 million of sublease income and $0.1 million of sublease expense, which is recorded in interest and other income, net in the consolidated statements of operations and comprehensive loss. On September 15, 2014, the Company entered into a five-year lease for approximately 34,400 square feet of office and laboratory space in South San Francisco. The Company may extend the lease for an additional three year term. The initial annual lease payments are $1.3 million, increasing to $1.6 million in the final year of the agreement. The lease period commenced in January 2015. The Company received a lease abatement for the first three months of the lease term, which is recorded as deferred rent and recognized over the lease term. The Company has provided deposits for letters of credit totaling $0.3 million to secure its obligations under its leases, which have been classified as long-term assets on the Company’s consolidated balance sheet as of March 31, 2016. Rent expense, net was $0.3 million and $0.3 million for the three months ended March 31, 2016, and 2015, respectively. Contingencies From time to time, the Company may have contingent liabilities that arise in the ordinary course of business activities. The Company accrues for such a liability when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were no contingent liabilities requiring accrual or disclosure as of March 31, 2016, or December 31, 2015. Guarantees and Indemnifications The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to certain of these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company’s technology. The term of these indemnification arrangements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made. The Company indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws, and agreements providing for indemnification entered into with its officers and directors. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity. The maximum amount of potential future indemnification of directors and officers is unlimited; however, the Company currently holds director and officer liability insurance. This insurance allows the transfer of risk associated with its exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

3 Months Ended

Mar. 31, 2016

Stockholders Equity Note [Abstract]

Stockholders' Equity

7. Stockholders’ Equity

Common Stock Reserved for Issuance

The Company has reserved shares of common stock for issuance as follows:

	March 31, 2016		December 31, 2015
Options issued and outstanding		1,910,181		1,318,647
Shares available for issuance under 2015 Stock Option and Incentive Plan		942,611		1,497,071
Shares available for issuance under 2015 Employee Stock Purchase Plan		255,000		255,000
Total		3,107,792		3,070,718

Redeemable Convertible Preferred Stock

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

3 Months Ended

Mar. 31, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

8. Stock-Based Compensation

	Three Months Ended March 31,
	2016		2015
Research and development	$	174	$	18
General and administrative		240		17
Total	$	414	$	35

The following summarizes option activity under the 2012 Equity Incentive Plan and 2015 Stock Option and Incentive Plan:

	Shares Subject to			Weighted Average
	Outstanding Options			Exercise Price Per Share
Balance at December 31, 2015		1,318,647			2.29
Options granted		605,134			8.80
Options exercised		—			—
Options canceled		(13,600	)		10.00
Balance at March 31, 2016		1,910,181			4.30

XML 25 R14.htm IDEA: XBRL DOCUMENT

Net Loss per Share Attributable to Common Stockholders

3 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

Net Loss per Share Attributable to Common Stockholders

9. Net Loss per Share Attributable to Common Stockholders

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts):

	Three Months Ended March 31,
	2016			2015
Numerator
Net loss	$	(8,420	)	$	(4,500	)
Cumulative dividends on redeemable convertible preferred stock		—			(952	)
Accretion of redeemable convertible preferred stock to redemption value		—			(33	)
Net loss attributable to common stockholders, basic and diluted	$	(8,420	)	$	(5,485	)
Denominator
Weighted average shares outstanding		27,024,638			3,752,389
Less: weighted average shares subject to repurchase		(855,486	)		(1,530,638	)
Weighted average shares used to compute basic and diluted net loss per share		26,169,152			2,221,751
Net loss per share attributable to common stockholders: Basic and diluted	$	(0.32	)	$	(2.47	)

	March 31,
	2016		2015
Common stock subject to repurchase		806,035		1,465,685
Stock options to purchase common stock		1,910,181		458,887

XML 26 R15.htm IDEA: XBRL DOCUMENT

Related Party Transactions	3 Months Ended
Related Party Transactions	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	10. Related Party Transactions In September 2012, the Company began receiving consulting and management services pursuant to an unwritten agreement with Third Rock Ventures, which is one of the Company’s largest shareholders. Charles Homcy and Kevin Starr, both directors of the Company, are general partner and partner, respectively, of Third Rock Ventures. The consulting fees paid to Third Rock Ventures were incurred by the Company in the ordinary course of business, and were $22,000 and $31,000 for the three months ended March 31, 2016 and 2015, respectively. As of March 31, 2016 and December 31, 2015, the Company had an outstanding liability to Third Rock Ventures of $23,000 and $13,000. Effective July 29, 2013, the Company entered into a shared facilities and services agreement with GBT, a company that was majority-owned by Third Rock Ventures as of such date. In connection with that agreement, the Company reimbursed GBT for shared facilities and equipment of the Company’s former corporate headquarters location. During the three months ended March 31, 2016 and 2015, the Company reimbursed expenses and equipment of zero and $33,000, respectively, to GBT. There was no outstanding liability to GBT as of March 31, 2016 and December 31, 2015. In October 2014, the Company entered into a lease assignment agreement with the owner of the former headquarters building and GBT to allow GBT to sublease the Company’s portion of the office after the Company relocated to its new corporate headquarters.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

XML 27 R16.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2016
Accounting Policies [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s consolidated financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), the Company meets the definition of an emerging growth company, and has irrevocably elected to opt out of the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. In March 2016, the FASB issued Accounting Standard Update (“ASU”) No. 2016-10, Revenue from Contracts, which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU will provide a more robust framework for recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation. This framework will help to improve comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets and provide more useful information to users of financial statements through improved disclosure requirements. For a public entity, the amendments in ASU 2016-10 are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Company has not determined the potential effects of this standard on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Share-Based Compensation, with the objective to identify, evaluate, and improve areas of generally accepted accounting principles (GAAP) for which cost and complexity can be reduced while maintaining or improving the usefulness of the information provided to users of financial statements. The areas for simplification in ASU 2016-09 involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public business entities, the amendments in ASU 2016-09 are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for any entity in any interim or annual period. The Company is currently evaluating the impact of this standard on its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02 (Topic 842), Leases. ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has not determined the potential effects of this standard on its consolidated financial statements. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern. The new standard provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. ASU 2014-12 requires that a performance target that affects vesting and could be achieved after the requisite service period be treated as a performance condition. ASU 2014-12 is effective for the Company in its first quarter of 2016 with early adoption permitted. The Company has determined that the adoption of this standard did not have a material impact on its consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The ASU is effective for public entities for annual and interim periods beginning after December 15, 2017, with early adoption for fiscal 2017 permitted. The Company has not determined the potential effects of this standard on its consolidated financial statements.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2016

Fair Value Disclosures [Abstract]

Summary of Changes in Fair Value of Financial Instruments

The following table sets forth a summary of the changes in the fair value of the Company’s Level 1 financial instruments as follows (in thousands):

	Fair Value Measurements at March 31, 2016
	Total		Level 1		Level 2		Level 3
Assets
Money Market funds	$	99,060	$	99,060	$	—	$	—

	Fair Value Measurements at December 31, 2015
	Total		Level 1		Level 2		Level 3
Assets
Money Market funds	$	111,533	$	111,533	$	—	$	—

Summary of Changes in Fair Value of Company's Level 3 Financial Instruments

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments as follows (in thousands):

	Convertible preferred stock
	call option liability, net
Balance at December 31, 2014	$	314
Change in fair value recorded in statement of operations and comprehensive loss		(314	)
Balance at March 31, 2015	$	—

XML 29 R18.htm IDEA: XBRL DOCUMENT

Balance Sheet Components (Tables)

3 Months Ended

Mar. 31, 2016

Balance Sheet Related Disclosures [Abstract]

Summary of Property and Equipment

Property and equipment consist of the following (in thousands):

	March 31, 2016			December 31, 2015
Scientific equipment	$	4,462		$	3,995
Furniture and equipment		352			301
Capitalized software		225			225
Leasehold improvements		304			303
Total		5,343			4,824
Less: Accumulated depreciation and amortization		(2,336	)		(2,080	)
Property and equipment, net	$	3,007		$	2,744

Summary of Accrued Liabilities

Accrued liabilities consist of the following (in thousands):

	March 31, 2016		December 31, 2015
Payroll and related expenses	$	1,522	$	2,515
Clinical research and development		2,478		2,145
Legal and accounting fees		371		33
Other		456		940
Total accrued liabilities	$	4,827	$	5,633

XML 30 R19.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2016

Equity [Abstract]

Schedule of Common Stock Reserved for Issuance

The Company has reserved shares of common stock for issuance as follows:

	March 31, 2016		December 31, 2015
Options issued and outstanding		1,910,181		1,318,647
Shares available for issuance under 2015 Stock Option and Incentive Plan		942,611		1,497,071
Shares available for issuance under 2015 Employee Stock Purchase Plan		255,000		255,000
Total		3,107,792		3,070,718

XML 31 R20.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Stock-Based Compensation Expense Related to Options Granted to Employees and Consultants

The following table sets forth stock-based compensation expense related to options granted to employees and consultants for all periods presented (in thousands):

	Three Months Ended March 31,
	2016		2015
Research and development	$	174	$	18
General and administrative		240		17
Total	$	414	$	35

Summary of Stock Option Activity Under Plans

The following summarizes option activity under the 2012 Equity Incentive Plan and 2015 Stock Option and Incentive Plan:

	Shares Subject to			Weighted Average
	Outstanding Options			Exercise Price Per Share
Balance at December 31, 2015		1,318,647			2.29
Options granted		605,134			8.80
Options exercised		—			—
Options canceled		(13,600	)		10.00
Balance at March 31, 2016		1,910,181			4.30

XML 32 R21.htm IDEA: XBRL DOCUMENT

Net Loss per Share Attributable to Common Stockholders (Tables)

3 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net Loss per Share

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts):

	Three Months Ended March 31,
	2016			2015
Numerator
Net loss	$	(8,420	)	$	(4,500	)
Cumulative dividends on redeemable convertible preferred stock		—			(952	)
Accretion of redeemable convertible preferred stock to redemption value		—			(33	)
Net loss attributable to common stockholders, basic and diluted	$	(8,420	)	$	(5,485	)
Denominator
Weighted average shares outstanding		27,024,638			3,752,389
Less: weighted average shares subject to repurchase		(855,486	)		(1,530,638	)
Weighted average shares used to compute basic and diluted net loss per share		26,169,152			2,221,751
Net loss per share attributable to common stockholders: Basic and diluted	$	(0.32	)	$	(2.47	)

Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share

	March 31,
	2016		2015
Common stock subject to repurchase		806,035		1,465,685
Stock options to purchase common stock		1,910,181		458,887

XML 33 R22.htm IDEA: XBRL DOCUMENT

Formation and Business of the Company - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended
	Nov. 03, 2015	Mar. 31, 2015	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Accumulated deficit			$ (73,105)	$ (64,685)
Cash and cash equivalents		$ 35,617	$ 99,495	$ 112,265	$ 43,648
Net proceeds from initial public offering	$ 55,600
Series A, A-1 and Series B Redeemable Convertible Preferred Stock
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Net proceeds from sale of shares of convertible stock		$ 93,900
IPO
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Issuance of common stock	6,253,125
Shares issued, price per share	$ 10.00

XML 34 R23.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Details) - Fair Value Measurements on Recurring Basis - Money market funds - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Assets
Assets fair value	$ 99,060	$ 111,533
Level 1
Assets
Assets fair value	$ 99,060	$ 111,533

XML 35 R24.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Summary of Changes in Fair Value of Company's Level 3 Financial Instruments (Details) - Convertible Preferred Stock Call Option Liability, Net $ in Thousands	3 Months Ended
	Mar. 31, 2015 USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 314
Change in fair value recorded in statement of operations and comprehensive loss	$ (314)

XML 36 R25.htm IDEA: XBRL DOCUMENT

Collaboration and License Agreement - Additional Information (Details) - Sanofi (Aventis Inc.) - Collaborative Agreement	1 Months Ended		3 Months Ended		12 Months Ended
	Apr. 30, 2015 USD ($)	Aug. 31, 2014 USD ($) Program $ / shares shares	Mar. 31, 2016 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront cash received under collaboration agreement		$ 35,000,000
Initial equity investment		10,000,000
Eligible to receive milestone payment		$ 25,000,000
Period for research and clinical activities		4 years
Number of research programs \| Program		3
Deferred revenue		$ 35,000,000	$ 10,600,000		$ 14,200,000
Revenue recognized under collaboration agreement			$ 3,600,000	$ 3,600,000
One-time non-refundable non-creditable cash payment		45,000,000
Project continuation, additional payment		40,000,000
Project continuation, additional payment description			an additional $40.0 million in connection with the purchase of the Company’s preferred stock, assuming (i) the Company had not previously closed either a Qualified IPO (at which time this obligation would terminate) or a private financing prior to a Qualified IPO and (ii) Sanofi had not previously purchased shares of the Company’s stock pursuant to such rights to purchase the Company’s capital stock in accordance with the terms of the Collaboration Agreement.
Time restricted rights to purchase stock, value			$ 40,000,000
Convertible preferred stock at discount			$ 40,000,000
Redeemable convertible preferred stock call option liability fair value		$ 700,000
Change in fair value of redeemable convertible preferred stock call option liability					$ (300,000)	$ (400,000)
Series A-1 Redeemable Convertible Preferred Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of common stock \| shares		6,666,667
Fair value of stock per share price \| $ / shares		$ 1.50
Series B Redeemable Convertible Preferred Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Project continuation, additional payment	$ 35,000,000
Decrease in project continuation additional payment	$ 5,000,000
Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Proceeds from collaboration agreement		$ 200,000,000
Project continuation payment		85,000,000
Funding from approved in-kind research and clinical activities		$ 45,000,000

XML 37 R26.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Line Items]
Property and equipment	$ 5,343	$ 4,824
Less: Accumulated depreciation and amortization	(2,336)	(2,080)
Property and equipment, net	3,007	2,744
Scientific Equipment
Property Plant And Equipment [Line Items]
Property and equipment	4,462	3,995
Furniture and Equipment
Property Plant And Equipment [Line Items]
Property and equipment	352	301
Capitalized Software
Property Plant And Equipment [Line Items]
Property and equipment	225	225
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment	$ 304	$ 303

XML 38 R27.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Balance Sheet Related Disclosures [Abstract]
Depreciation and amortization	$ 256	$ 254

XML 39 R28.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Balance Sheet Related Disclosures [Abstract]
Payroll and related expenses	$ 1,522	$ 2,515
Clinical research and development	2,478	2,145
Legal and accounting fees	371	33
Other	456	940
Total accrued liabilities	$ 4,827	$ 5,633

XML 40 R29.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Details)			3 Months Ended
	Sep. 15, 2014 USD ($) ft²	Jun. 29, 2012 USD ($) ft²	Mar. 31, 2016 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2015 USD ($)
Commitments And Contingencies Disclosure [Line Items]
Purchase commitment cancellation notice period			30 days
Other long term assets			$ 289,000		$ 289,000
Rent expense net			300,000	$ 300,000
Contingent liability for accrual			0		$ 0
Facility Leases Member
Commitments And Contingencies Disclosure [Line Items]
Lease period	5 years	66 months
Area of leased property \| ft²	34,400	12,000
Annual lease payments		$ 500,000
Sublease income			100,000
Sublease expense			$ 100,000
Additional period of extension in lease contract	3 years
Initial annual lease payments	$ 1,300,000
Increase in lease payments at final year of agreement	$ 1,600,000
Lease commencement period			2015-01
Lease abatement period			3 months

XML 41 R30.htm IDEA: XBRL DOCUMENT

Stockholders' Equity- Schedule of Common Stock Reserved for Issuance(Details) - shares	Mar. 31, 2016	Dec. 31, 2015
Class Of Stock [Line Items]
Shares reserved for future issuance, shares	3,107,792	3,070,718
Options Issued and Outstanding
Class Of Stock [Line Items]
Shares reserved for future issuance, shares	1,910,181	1,318,647
2015 Stock Option and Incentive Plan
Class Of Stock [Line Items]
Shares reserved for future issuance, shares	942,611	1,497,071
2015 Employee Stock Purchase Plan
Class Of Stock [Line Items]
Shares reserved for future issuance, shares	255,000	255,000

XML 42 R31.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2015	Oct. 31, 2015
Class Of Stock [Line Items]
Accretion of redeemable convertible preferred stock to redemption value	$ 33
Accretion of dividends on redeemable convertible preferred stock	$ 952
Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Redeemable convertible preferred stock, shares outstanding		62,235,313
Redeemable convertible preferred stock, par value		$ 0.0001
Series A Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Redeemable convertible preferred stock, shares outstanding		38,500,000
Series A-1 Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Redeemable convertible preferred stock, shares outstanding		6,666,667
Series B Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Redeemable convertible preferred stock, shares outstanding		17,068,646

XML 43 R32.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Options Granted to Employees and Consultants (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 414	$ 35
Research and development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	174	18
General and administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 240	$ 17

XML 44 R33.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Stock Option Activity Under Plans (Details)	3 Months Ended
	Mar. 31, 2016 $ / shares shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shares Subject to Outstanding Options, Beginning Balance \| shares	1,318,647
Shares Subject to Outstanding Options, granted \| shares	605,134
Shares Subject to Outstanding Options, canceled \| shares	(13,600)
Shares Subject to Outstanding Options, Ending Balance \| shares	1,910,181
Weighted Average Exercise Price Per Share, Beginning Balance \| $ / shares	$ 2.29
Weighted Average Exercise Price Per Share, granted \| $ / shares	8.80
Weighted Average Exercise Price Per Share, cancelled \| $ / shares	10.00
Weighted Average Exercise Price Per Share, Ending Balance \| $ / shares	$ 4.30

XML 45 R34.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Additional Information (Details)	Mar. 31, 2016 USD ($)
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Unrecognized share based compensation expense	$ 0

XML 46 R35.htm IDEA: XBRL DOCUMENT

Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Numerator
Net loss	$ (8,420)	$ (4,500)
Cumulative dividend relating to redeemable convertible preferred stock		(952)
Accretion of redeemable convertible preferred stock to redemption value		(33)
Net loss attributable to common stockholders	$ (8,420)	$ (5,485)
Denominator
Weighted average shares outstanding	27,024,638	3,752,389
Less: weighted average shares subject to repurchase	(855,486)	(1,530,638)
Weighted average shares used to compute basic and diluted net loss per share	26,169,152	2,221,751
Net loss per share attributable to common stockholders:
Basic and diluted	$ (0.32)	$ (2.47)

XML 47 R36.htm IDEA: XBRL DOCUMENT

Net Loss per Share Attributable to Common Stockholders - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Common stock subject to repurchase
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from earnings per share	806,035	1,465,685
Stock options to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from earnings per share	1,910,181	458,887

XML 48 R37.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Third Rock Ventures
Related Party Transaction [Line Items]
Related party costs	$ 22,000	$ 31,000
Due to related parties	23,000		$ 13,000
GBT
Related Party Transaction [Line Items]
Due to related parties	0		$ 0
Company reimbursed expenses and equipment	$ 0	$ 33,000

EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 50 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 68 152 1 false 27 0 false 5 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.myokardia.com/20160331/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.myokardia.com/20160331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.myokardia.com/20160331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.myokardia.com/20160331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.myokardia.com/20160331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 100050 - Disclosure - Formation and Business of the Company Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureFormationAndBusinessOfCompany Formation and Business of the Company Notes 6 false false R7.htm 100060 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 100070 - Disclosure - Fair Value Measurements Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 8 false false R9.htm 100080 - Disclosure - Collaboration and License Agreement Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureCollaborationAndLicenseAgreement Collaboration and License Agreement Notes 9 false false R10.htm 100090 - Disclosure - Balance Sheet Components Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureBalanceSheetComponents Balance Sheet Components Notes 10 false false R11.htm 100100 - Disclosure - Commitments and Contingencies Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 11 false false R12.htm 100110 - Disclosure - Stockholders' Equity Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 12 false false R13.htm 100120 - Disclosure - Stock-Based Compensation Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 13 false false R14.htm 100130 - Disclosure - Net Loss per Share Attributable to Common Stockholders Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders Net Loss per Share Attributable to Common Stockholders Notes 14 false false R15.htm 100140 - Disclosure - Related Party Transactions Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 15 false false R16.htm 100150 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.myokardia.com/20160331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 16 false false R17.htm 100160 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.myokardia.com/20160331/taxonomy/role/DisclosureFairValueMeasurements 17 false false R18.htm 100170 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureBalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://www.myokardia.com/20160331/taxonomy/role/DisclosureBalanceSheetComponents 18 false false R19.htm 100180 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.myokardia.com/20160331/taxonomy/role/DisclosureStockholdersEquity 19 false false R20.htm 100190 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.myokardia.com/20160331/taxonomy/role/DisclosureStockBasedCompensation 20 false false R21.htm 100200 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables Net Loss per Share Attributable to Common Stockholders (Tables) Tables http://www.myokardia.com/20160331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders 21 false false R22.htm 100210 - Disclosure - Formation and Business of the Company - Additional Information (Details) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails Formation and Business of the Company - Additional Information (Details) Details 22 false false R23.htm 100220 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Details) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetails Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Details) Details 23 false false R24.htm 100230 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Company's Level 3 Financial Instruments (Details) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfCompanySLevel3FinancialInstrumentsDetails Fair Value Measurements - Summary of Changes in Fair Value of Company's Level 3 Financial Instruments (Details) Details 24 false false R25.htm 100240 - Disclosure - Collaboration and License Agreement - Additional Information (Details) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails Collaboration and License Agreement - Additional Information (Details) Details 25 false false R26.htm 100250 - Disclosure - Balance Sheet Components - Summary of Property and Equipment (Details) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails Balance Sheet Components - Summary of Property and Equipment (Details) Details 26 false false R27.htm 100260 - Disclosure - Balance Sheet Components - Additional Information (Details) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails Balance Sheet Components - Additional Information (Details) Details 27 false false R28.htm 100270 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Details) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails Balance Sheet Components - Summary of Accrued Liabilities (Details) Details 28 false false R29.htm 100280 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 29 false false R30.htm 100290 - Disclosure - Stockholders' Equity- Schedule of Common Stock Reserved for Issuance(Details) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForIssuanceDetails Stockholders' Equity- Schedule of Common Stock Reserved for Issuance(Details) Details 30 false false R31.htm 100300 - Disclosure - Stockholders' Equity - Additional Information (Details) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails Stockholders' Equity - Additional Information (Details) Details 31 false false R32.htm 100310 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Options Granted to Employees and Consultants (Details) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToOptionsGrantedToEmployeesAndConsultantsDetails Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Options Granted to Employees and Consultants (Details) Details 32 false false R33.htm 100320 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity Under Plans (Details) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails Stock-Based Compensation - Summary of Stock Option Activity Under Plans (Details) Details 33 false false R34.htm 100330 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 34 false false R35.htm 100340 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Details) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareDetails Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Details) Details 35 false false R36.htm 100350 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails Net Loss per Share Attributable to Common Stockholders - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details) Details 36 false false R37.htm 100360 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://www.myokardia.com/20160331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 37 false false All Reports Book All Reports myok-20160331.xml myok-20160331.xsd myok-20160331_cal.xml myok-20160331_def.xml myok-20160331_lab.xml myok-20160331_pre.xml true true ZIP 55 0001564590-16-019213-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-16-019213-xbrl.zip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ī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end